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Experimental and epidemiological evidence supports the role of chronic arsenic 
exposure in a broad scope of adverse health effects at a wide range of exposure levels. 
However, little is known regarding arsenic metabolism and health risk. The objective 
of this dissertation was to investigate the role of arsenic metabolism in mortality, 
diabetes, and kidney disease.    
First, we conducted a systematic review of the epidemiologic evidence 
examining the relation between arsenic metabolism and cancer, cardiovascular 
diseases, and adiposity. We identified 12 eligible studies for cancer, 9 for 
cardiovascular diseases, and 7 for adiposity. The higher proportion of 
monomethylarsonate [MMA%] in the urine tended to be associated with cancer and 
cardiovascular disease risk, whereas the lower MMA% tended to associated with an 
increase in adiposity. However, rather heterogeneous statistical approaches and 
limited prospective evidence prevented a conclusive inference from this review. In 
variability analysis, the range of between-population variation in MMA% is relatively 
narrow compared to the proportion of inorganic arsenic [iAs%] and dimethylarsinate 
[DMA%] in urine.   
Second, we measured arsenic metabolism defined by relative proportions of 
inorganic arsenic, MMA and DMA over their sum in the baseline urine of Strong 
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Heart Study participants aged 45-74 years to evaluate the role of arsenic metabolism 
in all-cause, cardiovascular disease and cancer mortality. The adjusted hazard ratio of 
all-cause mortality for an interquartile increase in DMA% was 1.16 (95% CI 1.01-
1.33) when it substituted iAs% whereas MMA% did not explain the risk of all-cause 
mortality. For cardiovascular mortality, the adjusted hazard ratio for an interquartile 
change increase in MMA% was 1.52 (1.16-1.99) and 1.17 (1.01-1.35) when it 
substituted iAs% and DMA%, respectively. For cancer mortality, the adjusted hazard 
ratio for an interquartile increase in MMA% was 0.73 (0.55-0.98) and 0.81 (0.67-
0.97) when it substituted iAs% and DMA%, respectively.  
Third, we examine the prospective association between arsenic metabolism and 
diabetes in the Strong Heart Study. The adjusted hazard ratios of diabetes for an 
interquartile range increase in MMA% was 0.69 (95% CI 0.52-0.90) and 0.76 (0.65-
0.89) when it was substituted for iAs% and DMA%, respectively. The association 
between arsenic metabolism and diabetes was similar by age, sex, study site, obesity, 
and the sum of inorganic and methylated arsenic concentrations.  
Fourth, we evaluated the role of arsenic metabolism in the development of 
chronic kidney disease among Strong Heart Study participants without baseline 
kidney disease. Incident kidney disease was defined by estimated glomerular filtration 
rate(eGFR) <60 ml/min/1.73m2 with a drop in eGFR ≥ 25%. The adjusted hazard 
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ratio for an interquartile range increase in MMA% was 1.76 (95% CI 1.26-2.47) and 
1.22 (1.02-1.45) when it was substituted for iAs% and DMA%, respectively. And 
when an interquartile range increase in DMA% with a corresponding decrease in 
iAs%, the adjusted hazard ratio was 1.83 (95% CI 1.29-2.61).  
In conclusion, arsenic metabolism was significantly associated with the risk of 
mortality, diabetes, and kidney disease and the associations were independent of total 
chronic arsenic exposure. Our results support that urine biomarkers of arsenic 
metabolism may reflect individual susceptibility to arsenic-related health effects and 
provide a novel perspective on the dynamic modeling of arsenic metabolism. In 
addition to replicating these finding across diverse populations and geographical areas 
to advance risk assessment and risk management of arsenic, future research needs to 
evaluate mechanisms for the connection between arsenic metabolism and health 
outcomes.  
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Specific aims  
Arsenic metabolism refers to the process of how arsenic is methylated and 
transformed into arsenic metabolites in the human body. There is a substantial inter-
individual variation in arsenic methylation efficiency.1, 2 The biological meaning 
underlying this variation, however, remains poorly understood. Increasing 
epidemiologic evidence supports arsenic metabolism as an important determinant of 
individual susceptibility to the adverse effects of inorganic exposure including 
cancers3, cardiovascular diseases4, and diabetes mellitus (DM).5 Most studies were 
cross-sectional and case-control in design with relatively small samples and high 
levels of arsenic exposure. For US populations, arsenic exposure is pervasive through 
drinking water and foods especially in small rural communities affected by low-to-
moderate arsenic levels in drinking water .6, 7 The associations between low-moderate 
arsenic exposure, cardiovascular disease, and type 2 DM has been recently reported in 
both cross-sectional and prospective studies.8-11 Yet, little is known about the impact 
of low-moderate arsenic exposure in all-cause mortality and kidney diseases and 
large prospective evidence examining the association between arsenic metabolism and 
non-cancer outcomes at levels of arsenic exposure relevant to US populations is 




The first objective of this project is to evaluate the role of arsenic metabolism 
in mortality from all-cause, cardiovascular disease, and cancer among participants 
in the Strong Heart Study (SHS). Starting in 1989, the SHS recruited resident 
members in American-Indians (age 45-74 years) from communities in Arizona, 
Oklahoma and the North and South Dakotas to investigate the development of 
obesity, diabetes and cardiovascular diseases.12 The second objective is to estimate 
the association of arsenic metabolism and arsenic exposure on incident diabetes. The 
increasing prevalence of type 2 DM poses a major public health challenge and 
diabetes is strongly associated with all-cause mortality, cardiovascular morbidities, 
and ends stage renal disease.13, 14 Although large evidence supports the role of arsenic 
exposure in the development of diabetes,15 the debate about the causality of the 
association remains unsettled, especially at low-moderate levels of arsenic exposure.16 
Especially, very few studies have evaluated the role of arsenic metabolism in the 
development of diabetes. The third objective is to evaluate the role of arsenic in the 
development of chronic kidney diseases (CKD). Chronic kidney disease is a 
significant global health issue with prevalence 8-16% worldwide and the burden of 
CKD is also rising due to multiple organ complications and increased all-cause and 
cardiovascular mortality.17-19 Growing evidence links inorganic arsenic exposure to 
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diverse renal injuries including proteinuria20, chronic kidney disease21, and proximal 
tubular dysfunction .22 Characterizing the potential role of arsenic exposure and 
arsenic metabolism provides a novel perspective on CKD prevention. Given the 
widespread exposure to arsenic and the high mortality rate and high incident diabetes 
in American Indians, our study can inform integrated risk assessment of arsenic 
toxicity and arsenic metabolism and advance the prevention  of diabetes and CKD.  
 The specific aims of this dissertation are the following:  
1. To conduct a systematic review of the epidemiologic association between 
arsenic metabolism and cancer, cardiovascular disease and adiposity/diabetic 
phenotypes. While an increasing number of studies have evaluated the 
association between arsenic metabolism and disease, no systematic review has 
been previously conducted on this topic. 
2. To evaluate the association of long-term arsenic exposure and metabolism 
with all-cause, cardiovascular, and cancer mortality. Arsenic exposure was 
assessed based on the sum of inorganic, monomethylated (MMA) and 
dimethylated (DMA) arsenic species in urine. Arsenic metabolism was assessed 
based on the relative proportion of inorganic arsenic, MMA and DMA over their 
sum. We have previously confirmed the long-term stability of urine arsenic 
concentrations and methylation patterns over 10 years in this population, 
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supporting the use of a single urine sample to assess arsenic internal dose and 
metabolism in this study.23 Causes of death were determined by the SHS Mortality 
Review Committee based on the standardized mortality surveillance procedures, 
including discharge summary of the terminal hospital admission, medical reports, 
autopsy, and pathology report if available8.   
3. To evaluate the association of long-term arsenic exposure and metabolism 
with the incidence of type 2 diabetes. We hypothesized that inorganic arsenic 
exposure is associated with increased risk of incident diabetes as arsenic has been 
linked to various diabetogenic mechanisms including beta-cell dysfunction and 
systemic insulin resistance.24-26 We also hypothesized that different arsenic 
methylation capacity predisposes the individual to incident diabetes. We used the 
measures of arsenic exposure and metabolism described in aim 1 to evaluate the 
prospective association between arsenic exposure, arsenic metabolism and 
incident diabetes. Diabetes will be defined according to the latest World Health 
Organization (WHO) guideline using measures currently available for all SHS 
participants at baseline and up to 2 follow-up visits.27  
4. To evaluate the association of long-term arsenic exposure and metabolism 
with incident chronic kidney diseases.  We hypothesized that vascular 
inflammation and endothelial dysfunction induced by inorganic arsenic may be 
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associated with the development of chronic kidney diseases20. We also 
hypothesized that differential arsenic biotransformation capacity links to different 
incident CKD risk. We used the measures of arsenic exposure and metabolism 
described in aim 1 to evaluate the incidence of CKD among participants with 
baseline estimated glomerular filtration rate higher than 60 ml/min/1.73m2. CKD 
was defined by four commonly adopted definitions in cohort studies including 1) 
an eGFR less than 60 ml/min/1.73m2; 2) an eGFR less than 60 ml/min/1.73m2 and 
a drop in eGFR of at least 25%; 3) an eGFR less than 60 ml/min/1.73m2 and a 
drop in eGFR of at least 25% and with macroalbuminuria (urine albumin-
creatinine ratio ≥ 300 mg/g creatinine); 4) doubling serum creatinine levels or 
progression to end-stage renal disease (ESRD)28, 29.   Associations were adjusted 
for risk factors of cardiovascular diseases including hypertension and diabetes.  
The SHS is the largest population-based study of diabetes and cardiometabolic 
diseases in American Indians (Figure 1)12, 30. Exposure to a wide range of low-
moderate inorganic arsenic, a high mortality rate, a high burden of diabetes and 
obesity and a low seafood exposure make an excellent opportunity to study the 
adverse health effects of inorganic arsenic in this population with the potential to 
generalize study results to the general U.S. population which also has low-moderate 





Overview of arsenic metabolism 
Biotransformation of arsenic in human 
Inorganic arsenic is metabolized in the human body. After absorption, the 
inorganic forms (arsenate and arsenite) are methylated into monomethylarsonate 
[MMA] and dimethylarsinate [DMA]) mainly in the liver and excreted in the urine 
through kidney (Figure 2).31, 32 Among many proposed arsenic biotransformation 
pathways33-38, two inorganic arsenic metabolic pathways have been commonly 
described: 1) Classical oxidative methylation pathway (Challenger pathway) 
involving sequential steps from As[V]) → arsenite (As[III]) → monomethylarsonate 
(MMA[V]) → monomethylarsonite (MMA[III]) → dimethylarsinate (DMA[V]) → 
dimethylarsinite (DMA[III])33, 34, 39; 2) Alternate reductive methylation pathway 
(Hayakawa pathway) involving the conjugation between arsenite(As[III]) and 
glutathione(GSH) from transsulfuration pathway and a subsequent methylation from 
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arsenotriglutathione(As[III](GS)3) → monomethylarsenodiglutathione 
(MMA[III](GS)2) → dimethylarsenoglutathione (DMA[III](GS)).
35 The oxidation of 
MMA[III](GS)2 and DMA[III](GS) to MMA[V] and DMA[V] could be separated and 
does not have to be sequential.35, 39 Overall, the exact biotransformation pathway of 
arsenic remains not fully understood after about 60 years of research in this domain, 
Cullen et al. recently summarized various perspectives on arsenic biomethylation and 
concluded that the Challenger pathway remains the most rational possibility.38  The 
relative toxicities of the arsenic metabolites has been proposed based on genotoxicity 
largely from cell culture studies in the following rank: MMA[III] > DMA[III] > 
As[III] > As[V] > MMA[V] > DMA[V].40 However, the feasibility to generalize this 




Figure 2. Proposed inorganic arsenic oxidative 










Determinants of arsenic metabolism 
In humans, the average distribution of arsenic metabolites in urine is 10-30% 
inorganic arsenic, 10-20% MMA and 60-80% DMA,41-43 with both substantial intra-
individual and inter-individual variation.44-47 Similar to other biochemical methylation 
processes, the contributions of both genetic and environmental factors to the inter-
individual variability of arsenic metabolism are widely acknowledged.46 Probably, the 
most well-known genetic variation involving the arsenic methylation efficiency is the 
genetic polymorphism around the arsenic methyltransferase (AS3MT, previously 
CYT19) gene, which has been supported by both genome-wide association studies 
(GWAS) and candidate gene studies.48, 49  Environmental factors may also influence 
the arsenic metabolism though the underlying mechanisms remain unclear.6, 50 Several 
external environmental factors including arsenic exposure dose, smoking, alcohol 
drinking, and nutrition status have been related to the individual variation of arsenic 
metabolism profile.6, 50 Although there was no conclusive evidence to support causal 
relationships between these external factors and methylation capacity, recent progress 
has been made regarding the role of nutritional modification (e.g. folate 
supplementation) in enhancing arsenic methylation efficiency to mitigate arsenic 
toxicities.51 On the other hand, internal environmental factors including age, sex, 
pregnancy, co-morbidities, and body mass index have been linked to the modification 
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of arsenic methylation capacity.50, 52, 53 However, inconsistent results were reported in 
the current literature suggesting a need to refine study design and statistical 
methodology to better clarify the associations among arsenic metabolism, age, sex, 
pregnancy, and body fat composition.50   
Health effects of arsenic metabolism  
Certain patterns of arsenic metabolism have been linked to the risk of 
developing cancer, cardiovascular disease, and adiposity. For instance, higher 
MMA% and lower DMA% in urine has been related to increased risk of cancer54-56 
and cardiovascular disease.57, 58 The increased risk of cancer and cardiovascular 
disease associated with higher MMA% in urine may be related to the high toxicity of 
MMA[III], which is also associated with insulin resistance in adipocytes.59-63 DMA 
has long been regarded as a less toxic arsenic specie, although DMA [III] has been 
recently linked to the prevalence of diabetes in studies from Mexico and Bangladesh.5, 
64 However, recent research has also connected lower MMA% and higher DMA% 
with an increase in adiposity. As an up-to-date review of existing studies is lacking, 
we conducted a systematic review (Chapter 2) to describe key gaps in current arsenic 




Crosstalk between arsenic metabolism and one-carbon metabolism.  
The main biochemical pathway to facilitate the arsenic metabolism is one-
carbon metabolism composed of three major units: folate cycle, methionine cycle, and 
transsulfuration pathway (figure 3).65, 66 Perturbation of these cycles has been linked 
to increased risk of mortality, cancer, and cardiovascular diseases and may also 
influence the efficiency of arsenic metabolism.65, 67-69 For malnourished populations in 
Bangladesh, the methylation capacity can be enhanced with short-term folate 
supplementation.51 Conversely, arsenic exposure may also disturb the dynamic 
balance of one-carbon metabolism and its associated biochemical reactions including 
DNA methylation, redox regulation including homocysteine and glutathione 
metabolism, and other xenobiotic metabolic pathways.6, 65, 70-72 To advance our 
understanding of how arsenic metabolism interacts with one-carbon metabolism, the 
fundamental step is to examine the association between arsenic metabolism and a 
spectrum of disease phenotypes related to one-carbon metabolism. This dissertation 
aims to inform biological meaning of arsenic metabolism and explore the complexity 
and challenges of the integrated risk assessment of arsenic.   
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Figure 3.  Cross talks between arsenic metabolism 
and one-carbon metabolism.  
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Objective  To systematically investigate the role of arsenic metabolism in the 
development of cancer, cardiovascular diseases, adiposity, and diabetic phenotypes and 
characterize the variation of arsenic metabolism in different populations worldwide.   
Design  Systematic review of observational studies 
Data sources  Medline/PubMed and EMBASE for relevant studies from inception to 
April 2014.  
Eligibility criteria for selecting studies  Observational studies that assessed the 
association between arsenic metabolism and health outcomes of interest including cancer, 
cardiovascular disease, and adiposity/diabetic phenotypes.  
Results  Twenty eight studies met the inclusion criteria, 12 on cancer, 9 on 
cardiovascular diseases, and 7 on adiposity and diabetic phenotypes. The median with 
interquartile range for iAs%, MMA%, and DMA% was 11.2 (7.8-14.9), 13(10.4-13.6), 
and 74.9(69.8-80.0), respectively.  MMA% has the lowest inter-population variance and 
per doubling change in urine arsenic concentration was associated with 0.02% (95% CI, -
0.7~0.6). For cancer, the patterns of a higher MMA% and a lower DMA% was associated 
with higher risk of developing all-site, urothelial, lung and skin cancers.  For 
cardiovascular disease, a higher MMA% was associated with higher risk of carotid 
atherosclerosis and cardiovascular diseases but not hypertension. For adiposity and 
diabetic phenotypes, the pattern of a lower MMA% and a higher DMA% was associated 
with higher body mass index and higher metabolic syndrome risk.    
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Conclusion  Although certain specific methylation patterns were identified to associate 
with disease risk, scopes and conclusions are constrained due to small sample size, 
limited prospective evidence, and inconsistent statistical approach. Relative constant 
MMA% across diverse populations is a novel finding from the mechanistic and 

















 Inorganic arsenic exposure through drinking water and food is a global 
environmental health problem.1   Chronic arsenic exposure affects multiple organ systems 
resulting in various cancers and cardiovascular diseases, and maybe also in respiratory 
disease, diabetes, and kidney disease2. The World Health Organization (WHO) and U.S. 
Agency for Toxic Substances and Disease Registry (ATSDR) have ranked arsenic as top 
priority for rigorous risk assessment and exposure control.3,4 Arsenic risk assessment, 
furthermore, is complicated by inter-individual variation in arsenic metabolism. After 
absorption, inorganic arsenic (arsenate and arsenite) is methylated into monomethylated 
and dimethylated arsenic compounds (MMA, DMA), which are then excreted through the 
kidney together with inorganic arsenic5. The average distribution of arsenic metabolites 
in urine has been reported to be 10-30% inorganic arsenic, 10-20% MMA and 60-80% 
DMA, with substantial inter-population and intra-population variations6-9.  Higher levels 
of MMA% and lower levels of DMA% have been related to cancer and cardiovascular 
outcomes in populations from Taiwan, Bangladesh and Argentina10-13. Lower levels of 
MMA% and higher levels of DMA%, on the other hand, have been related to higher body 
mass index and metabolic syndrome14-16. 
Arsenic metabolism is tightly connected to one-carbon metabolism,17 which is 
composed of three key cycles including the methionine cycle, the folate cycle, and the 
cysteine-cystathionine cycle18,19.  The major methyl donor in the body, S-
adenosylmethionine (SAM), is generated through the methionine cycle, to facilitate more 
than 50 methylation reactions in the body, including DNA methylation and arsenic 
methylation.20,21 The methionine cycle is completed by the re-methylation of 
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homocysteine back to methionine, through the folate cycle,22 or by irreversibly degrading 
homocysteine into cysteine.23  Dysfunction of the methionine cycle has been linked to 
chronic diseases including cancer and cardiovascular disease.19,24  The cysteine-
cystathionine cycle involves the glutathione-transsulfuration pathway and generates anti-
oxidant thio buffers, which are critical to maintain intracellular reduction-oxidation 
status.25 This pathway may also assist arsenic methyltransferase (AS3MT) to reductively 
methylated inorganic arsenic21. The imbalance of redox status has also been linked to 
cancer metabolism26,27, cardiovascular disease28, and diabetes29.   The intertwined 
relationship between arsenic metabolism and one-carbon metabolism may explain the 
individual susceptibility toward arsenic toxicity. Arsenic methylation pattern may also be 
used to estimate the gene-environment interaction. 
An increasing number of studies have evaluated the role of arsenic metabolism in 
the development of cancer,30,31 cardiovascular diseases,13 adiposity16, and diabetes32. The 
available evidence, however, has not been formally and comprehensively evaluated.  Our 
study objectives were, first, to conduct a systematic review to examine the role of arsenic 
metabolism in the development of cancer, cardiovascular disease, diabetes and adiposity, 
and second, to characterize the arsenic metabolism in different populations worldwide.  
 
Methods 
Search strategy and study selection 
The systematic search and review processes were conducted in accordance with 
the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 
Statement criteria33. We searched PubMed/Medline and EMBASE for original 
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epidemiologic studies investigating the role of arsenic metabolism in the risk of cancer, 
cardiovascular disease, and diabetes. For arsenic metabolism, we used the following 
MeSH terms: “arsenic”, “methylation”, “metabolism”, “arsenic metabolism”, “arsenic 
methylation” combining with other specific text-word terms related to the key research 
concepts. During the screening, evidence investigating the association between arsenic 
metabolism and diabetes was limited. Therefore, we also included studies using adiposity 
or prediabetes as main end point of interest.   (Supplementary table 1) shows the full 
search strategies. The search period was January 1966 through February 2014. There 
were no language restrictions. We also manually reviewed the reference lists from 
relevant original research.   
 Our primary exclusion criteria to screen records were: 1) publications contain no 
original research (reviews, editorials, non-research letters); 2) case reports and case 
series; 3) studies did not measure cancer, cardiovascular disease, diabetes (including 
prediabetes and metabolic syndrome), or adiposity (including obesity and body mass 
index); 4) studies did not have information on arsenic metabolism, as measured in urine 
(percentage [%] or ratios of urine arsenic metabolites). The secondary exclusion criteria 
included: 1) Lack of report of the association between arsenic metabolism and the study 
outcome; 2) Studies focused only on arsenic-related skin lesions (pre-malignancy); 3) 
pregnant population; 4) Duplicate study source population with same study design and 
outcome of interest.  
 To characterize the arsenic metabolism across human populations worldwide, we 
selected 19 studies from the current and the previous review9 based on the following 
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criteria: 1) sample size larger than 30(2 studies were excluded); 2) For with studies with 
the same or overlapping population, we selected studies with largest sample size.  
Data abstraction 
 Two authors, C.C. Kuo and C.W. Tsai, independently abstracted data from the 
articles that met the selection criteria. They developed a data extraction form to record 
the study characteristics (authors, journal, years of publication, country, study design, and 
objectives); the participant characteristics (study population (general vs. occupational) 
and number of participants); outcome definitions; measure of arsenic metabolism (% or 
ratio of urine arsenic metabolites, continuous and/or categorical); and the results of the 
association analysis from the statistical models adjusted for the most covariates. To 
assess study quality, we adapted the criteria used by Longnecker et al. for observational 
studies (supplementary figure 2-4 ). Two authors, C.C. Kuo and C.W. Tsai, also 
conducted risk of bias assessment for each study. The disagreement was resolved by 
consensus. The domains related to exposure assessment, outcome definition and 
statistical modeling including covariate adjustment were considered to be important for 
this review.  
Statistical Methods 
 Study characteristics, population characteristics, outcome definitions, exposure 
measures, association measurements, and statistical models were summarized in a 
consistent manner. In each study, the following items were abstracted (or derived if not 
directly reported): the mean age and percentage of men, arsenic metabolism (percentage 
or ratio of urine arsenic metabolites) and urine total arsenic levels.  For studies providing 
the median or geometric mean, the arsenic metabolism of the largest subgroup were used; 
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otherwise, data from pooled analyses were recorded. For studies only providing risk 
estimates among subgroups (interaction table), the relative risks were recalculated using 
pooled data. Both arithmetic and compositional geometric mean and variance were 
estimated. The relationship between total urine arsenic level and arsenic metabolism were 
evaluated using compositional data analysis (CoDa).34 All statistical analysis were 
performed using packages, ggtern and compositions, in R 3.0.0.  
 
Results 
Twenty eight studies met the inclusion criteria, 12 on cancer, 9 on cardiovascular 
diseases, and 7 on adiposity and diabetic phenotypes (Supplementary figure 1). All 
studies were in English. The medians with interquartile range for iAs%, MMA%, 
DMA%, and total urine arsenic concentration were 11.2 (7.8-14.9), 13(10.4-13.6), 
74.9(69.8-80.0), and 100(50.8-206.5), respectively. The compositional geometric mean 
for iAs%, MMA%, and DMA% was 11.3, 12.3, and 76.4, respectively. The distribution 
and variability of arsenic metabolism worldwide were summarized in figure 1 and 2. 
Individually, MMA% has the lowest inter-population variance (Figure 2). 
Compositionally, the largest variance occurred between iAs% and methylated arsenic 
species (MMA% and DMA%)(Supplementary figure 5). In univariable regression 
analysis, per doubling change in urine total arsenic level was associated with a 2.1% 
(95% CI, 0.8-3.5) increase in iAs%, 0.02% decrease (95% CI, -0.7~0.6) in MMA%, and 
a 1.9% (95% CI -3.7~-0.2) decrease in DMA%. The findings were consistent with the 




Of the 12 studies, 3 were prospective cohort studies10,35,36 and 9 were case-control 
studies. Only five studies were conducted outside of Taiwan (Table 1).11,30,31,37,38  Of 
these five studies, the study populations were from Argentina and the United States11,30, 
Chile31, East Europe38, and United States.11,37 Studies from Putai township of Chiayi 
County and Tainan County in Taiwan (n=6) were from previous Blackfoot Disease 
(BFD) endemic area, characterized by high arsenic exposure in drinking water (>100 
µg/L).10,35,36,39-41 In contrast, only one study from Taipei City/County (n=1) was 
considered as low arsenic exposure (<100 µg/L in drinking water).42 Study populations 
from Argentina, California and Nevada in the US, and Chile were exposed to low-to-
moderate arsenic levels (<100 µg/L in drinking water).11,31 Study populations from New 
Hampshire, US and Eastern Europe were exposed to low-to moderate arsenic levels 
(<100 µg/L).37,38 A total of 5 studies evaluated the risk of urothelial cancers, five studies 
assessed skin cancer as the primary study outcome and two studies examined the risk of 
lung cancer(Table 1). One study from Taiwan reported the association between arsenic 
metabolism with all cancer incidence.36,43 Most studies validated outcomes based on 
pathological and medical information (Table 1).  
Arsenic metabolism was assessed based on the proportions of arsenic species in 
the urine (iAs%, MMA%, and DMA%) in 11 studies and based on the primary 
methylation index (PMI, the ratio of MMA over iAs) and secondary methylation index 
(SMI, the ratio of DMA over MMA) in 6 studies (all of them from Taiwan). One of three 
studies that reported PMI showed a positive association between PMI and the risk of 
urothelial carcinoma.42 All three studies that reported SMI suggested a negative 
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association between SMI and urothelial cancers.41,42,44 For iAs%, most studies from 
Taiwan showed a positive association between iAs% and cancer although one study 
conducted in Chile did not find the same pattern.31 For MMA% and DMA%, five of 7 
studies reporting both MMA% and DMA% supported that the pattern of a higher 
MMA% and a lower DMA% was associated with higher risk of developing all-site36, 
urothelial35,42, lung31 and skin cancers.38,40  
Cardiovascular disease 
Five of nine enrolled studies were conducted in Taiwan12,45-48, two from 
Bangladesh13,49, and two from China(Table 2).50,51All study populations were considered 
to have high arsenic exposure( >100 g/L in drinking water).  Three of the nine studies 
were prospective cohort studies13,47,48, and the other six were cross-sectional. The study 
outcomes included hypertension (n=4),45,47,50,51 carotid atherosclerosis (n=3),46,48,49  
incident cardiovascular diseases (n=1)13, and peripheral arterial disease (n=1).12  
Hypertension was defined using well-established guidelines. The diagnosis of carotid 
atherosclerosis and peripheral vascular disease were based on extracranial carotid 
Doppler ultrasound evaluation and ankle-brachial index (ABI), respectively.   
 Most studies from Taiwan and Bangladesh reported both iAs%, MMA%, and 
DMA% and methylation indices including PMI and SMI. For iAs% and DMA%, all 
studies showed no significant association with the cardiovascular outcomes of interest. 
For MMA%, there was no association with hypertension in all studies45,47,50,51 ; however, 
a higher MMA% was associated with higher risk of cardiovascular diseases in 
Bangladesh.13 Only one of 3 studies measuring intimal thickness supported that a higher 
MMA% was associated with higher risk of carotid atherosclerosis (Table 2).49 Among 4 
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studies evaluating the association between methylation indices (PMI and SMI) and 
various cardiovascular outcomes, only one found a positive association of PMI and a 
negative association of SMI with incident CVD.13  
Adiposity and diabetic phenotypes 
 Seven studies evaluated the associations between arsenic metabolism and 
adiposity and diabetes related outcomes (Table 3). All studies were published after 2010 
and were in English. Study populations were from Bangladesh32, Mexico14,52,53, 
Taiwan15,54, and the United States.16 Two studies were case-control studies15,32 and the 
rest of the studies were cross-sectional in design.  Most study populations were exposed 
to moderate-high arsenic levels (>100g/L in drinking water) except populations from 
Taipei, Taiwan54 and the Strong Heart Study cohort (Arizona, Oklahoma, North/South 
Dakota, US).16 Three studies evaluated diabetes or metabolic syndrome as the primary 
outcome15,32,52, three studies assessed the association between arsenic metabolism and 
body mass index (BMI)14,16,53, and one study reported the risk of having obesity in 
adolescents.54 The definitions of diabetes were slightly different. The study from Mexico 
defined diabetes based on fasting glucose levels and self-reported physician diagnosis, 
while the study from Bangladesh used self-reported physician diagnosis exclusively.  
In the two studies examining the relationship among diabetes, obesity and arsenic 
metabolism measured by proportions of arsenic metabolites in urine, there was no 
significant association.32,54 However, a significant association between the pattern of a 
lower MMA% and a higher DMA% and higher metabolic syndrome risk was found in a 
study from Taiwan.15 Three studies using BMI as primary end point all reported that 
lower MMA% associated with a higher BMI.14,16,53 
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 Four studies reported PMI and SMI in addition to the proportions of arsenic 
species. Three of them evaluated the association between PMI and SMI with diabetes and 
the metabolic syndrome. Only one study found a lower PMI and a higher SMI were 
associated with the risk of metabolic syndrome.15 A fourth study evaluated SMI with 
BMI, and found that higher SMI was associated with higher BMI.14   
   
Discussion  
 This systematic review identified a significant gap between toxicological 
understanding of arsenic metabolism and its epidemiological application in risk 
assessment. Most studies had a small sample size and were assessed as being unclear or 
high risk of bias especially for studies were conducted based on exposure-by-subgroup 
interaction analysis. In addition, the lack of consensus over an appropriate standardized 
statistical model for estimating the arsenic metabolism makes the interpretation of the 
results challenging. Although most studies consistently supported a higher MMA% and a 
lower DMA% were associated with the risk of developing cancer, the result should be 
cautiously generalized to other populations as 7 of 12 enrolled studies were conducted in 
Taiwan from the same research group with significant overlaps in study population. For 
cardiovascular diseases, the research group in Bangladesh found a positive prospective 
association between MMA% and incident cardiovascular diseases and a positive cross-
sectional association between MMA% and carotid atherosclerosis. However, no studies 
found any association between hypertension and arsenic metabolism. For adiposity, a 
consistent negative association between MMA% and BMI were found in all studies used 
BMI as the primary outcome measurement. However, the role of arsenic metabolism in 
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the development of diabetes and obesity remains inconclusive due to insufficient data and 
limited statistical power.   
 Substantial inter-population variability of arsenic metabolism has been recognized 
in two previous studies.6,55 However, those studies analyzed few populations from China, 
Chile, Mexico, and Taiwan. In the current review, we found MMA% has less variability 
compared to iAs% and DMA% across diverse populations. In addition, MMA% is the 
only composition of arsenic metabolism that is not affected by the arsenic exposure 
(Supplementary figure 6). This finding implied that the first methylation process of 
arsenic in human body is tightly regulated and the second methylation process might play 
an adaptive role in the arsenic metabolism. Genetic polymorphism has been considered a 
major determinant in large inter-individual variability of the arsenic methylation pattern. 
The external factors such as arsenic exposure status may be equally important in 
adjusting arsenic metabolism and high arsenic exposure may impede the overall 
methylation capacity in human while also keep relative constant MMA%. More research 
is needed to explore the biological meaning of this unique phenomenon.  
 Several important observations remain to be explained. First, the interaction 
between arsenic exposure levels and arsenic metabolism is not clearly determined. For 
example, in studies of urothelial carcinoma or bladder cancer, a higher MMA% was 
associated with the risk of developing urothelial cancers even in the study populations 
with low levels of arsenic exposure (Taipei, Taiwan).35,42 However, this pattern was only 
observed in studies of skin cancer with high arsenic exposure but not in a study with low 
arsenic exposure.37 Second, the discrepancy in results between prospective studies and 
the cross-sectional studies in cancer and carotid atherosclerosis risk raise the concern that 
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disease outcome may modify the profile of arsenic metabolism. Future studies with large 
sample size, appropriate baseline arsenic metabolism estimation, and sufficient long-term 
follow-up may help verify the prospective association between arsenic metabolism and 
disease of interest. Third, interpretation of methylation indices (both PMI and SMI) is 
challenging. It is difficult to predict whether the numerator or the denominator will have 
dominant effect to drive the methylation indices. Developing a simple and interpretable 
modeling of arsenic metabolism is a research priority. Fourth, appropriate statistical 
modeling of arsenic metabolism remains unsettled. For instance, thirteen of 28 studies 
(46.4%) in our review adjusted arsenic exposure to evaluate the effect of arsenic 
metabolism. As arsenic exposure may be a potential confounder and also a strong risk 
factor for many outcomes of interest, adjusting arsenic exposure facilitates the 
interpretation of the statistical results. In addition, each composition of arsenic 
metabolism is constrained to 1 because they are normalized artificially to the sum of 
inorganic and methylated arsenic species. Handling compositional data using modern 
statistical methods designed for unconstrained data may lead to inappropriate inferences. 
Although compositional data analysis (CoDa) is almost unknown in the field of 
biomedical research and its applicability in biomedicine remains unclear, incorporating 
CoDa in the sensitivity analyses in arsenic metabolism research may be useful to gauge 
the robustness of the statistical results using conventional approaches.   
  The biological meaning of arsenic metabolism may be beyond the susceptibility 
of arsenic toxicity and may be the maker to estimate both genetic control of sensitivity to 
the environment and environmental control of gene expression (the gene-environment 
interaction). The interplay between one-carbon metabolism, arsenic metabolism, and 
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DNA methylation provides an opportunity to explore the genomic coding, metabolism 
regulation, and phenotype expression from a mechanistic perspective.24 Increasing 
evidence supports the association between arsenic exposure and global DNA methylation 
status.56,57 Moreover, mathematical modeling to handle the complexity of one-carbon 
metabolism and the interaction between the one-carbon and arsenic metabolism has been 
initiated.58,59 The challenge of future research is to integrate metabolism modeling and 
epigenomics to evaluate current biomarkers and identify novel markers.   
  
Conclusion 
 This is the first systematic review evaluating the current evidence examining the 
association between arsenic metabolism and different chronic disease outcomes. 
Although certain specific methylation patterns were identified as associated with increase 
disease risk, scopes and conclusions are constrained due to small sample size, limited 
prospective evidence, and inconsistent statistical approaches. Conducting large 
prospective cohort studies in populations exposed to a wide range of arsenic exposure 
levels is critical to better characterize the dynamic of arsenic metabolism and factors that 
influence the individual metabolism patterns. Relative constant MMA% across diverse 
populations is a novel and interesting finding from the mechanistic and evolutionary 
perspectives. More population evidence is needed to confirm this finding. Using a family-
based case-control study is important to investigate the role of candidate-gene in arsenic 
toxicity and arsenic metabolism as such a study design would effective eliminate the 
concern of population stratification confounding.60 Understanding the biological and 
epidemiological meaning of arsenic metabolism could significantly improve the risk 
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assessment of arsenic toxicity and provide a potential tool for disease prediction, 
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Abbreviations of Table 1: CAE, cumulative arsenic exposure; CC, case control study; CO, prospective cohort study; DMA, dimethylarsinate; iAs, inorganic 
arsenic; MMA, monomethylarsonate; PMI, primary methylation index(MMA/iAs); SMI, secondary methylation index (DMA/MMA); RRe, estimated relative 
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Table 4. Summary of arsenic methylation pattern for different health outcomes. 
Health outcomes  iAs%  MMA%  DMA%  PMI  SMI 
Cancer            
All‐site cancer           
Chung 2009     NR   
Lung cancer           
Steinmaus 2010  NR   NR  NR  NR 
Melek 2014     NR  NR 
Skin cancer           
Hsueh 1997  NR   NR  NR  NR 
Yu 2000     NR   
Chen 2003  NR      
Leonardi 2012  NR    NR  NR 
Gilbert‐Diamond 2013       
Urothelial cancer           
Chen 2003  NR  NR  NR    
Steinmaus 2006  NR   NR  NR  NR 
Pu 2007       
Huang 2008       
Melek 2014     NR  NR 
Cardiovascular disease           
Chen 2013       
Carotid atherosclerosis           
Wu 2006  NR   NR  NR  NR 
Huang 2009       
Chen 2013       
Hypertension            
Huang 2007       
Wang 2011     NR  NR 
Li 2013     NR  NR 
Li 2013     NR  NR 
Adiposity and diabetes           
Body mass index           
Gomez‐Rubio 2011  NR   NR  NR   
Gomez‐Rubio 2012  NR   NR  NR  NR 
Gribble 2013     NR  NR 
Obesity           
Su 2012     NR  NR 
Metabolic syndrome           
Chen 2012  NR      
Diabetes mellitus           
Del Razo 2011  NR  NR  NR    
Nizam 2013       
Note: arrows stand for the direction of association; double arrows stand for the direction of 




Figure 1. The distribution of arsenic metabolism across populations worldwide.  
 
Population selection criteria: 
1. Studies with sample size>30 
2. For duplicate study population, the 
largest studies were selected.  
3. For studies providing median or 
geometric mean, the arsenic 
metabolism profile of the largest 
subgroup was selected, otherwise, 
pooled data were used. 
4. Six studies (not in our review) were 




















































































































Supplementary figure 2. Quality criteria applied and evaluation of the design and data analysis issued in selected studies on the 





















































































































All studies                         
    Did the authors report all proportions of arsenic metabolism?             
    Did the authors report both primary and secondary arsenic methylation indices ?             
    Were outcomes based on objective tests or standard criteria in  90% of study   
    participants? 
            
    Did the authors present internal comparisons within study participants?             
    Did the authors control for potential confounding risk factors at least including
     age, sex, and smoking? 
            
    Did the authors control for total arsenic exposure?              
Follow‐up studies                             
    Was loss to follow up independent of exposure?               
    Was the intensity of search of disease independent of exposure status?               
Case‐control and cross‐sectional studies?                         
    Were the data collected in a similar manner for all participants?             
    Were the same exclusion criteria applied to all participants?             
    Was the time period over which cases and noncases or exposed and 
    nonexposed participants were interviewed the same? 
               
    Was the interviewer blinded with respect to the case status of the person 
    interviewed? 
               
    Was the response rate among non‐cases at least 70%?              
    Were all cases interviewed within 6 months of diagnosis?             
    Was the study based on incident cases of diseases?              
    Were noncases people who, had they developed the disease, would have 
    been cases? 
               
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Supplementary figure 3. Quality criteria applied and evaluation of the design and data analysis issued in selected studies on the 
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Supplementary figure 4. Quality criteria applied and evaluation of the design and data analysis issued in selected studies on the 
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Supplementary table 2.  Variation array of the analyzed compositions of arsenic metabolism from 19 studies.  
  iAs%  MMA%  DMA%   
iAs%    0.21  0.27  Log‐ratio 
variance MMA%  1.09   0.06 


















Supplementary figure 5.  Coda-dendrogram of the isomeric log-ratio(ilr) basis for the compositions of arsenic metabolism. The 
horizontal green lines are proportional to the variance of each balance and the largest variance corresponds to the first balance 
comparing the inorganic arsenic and methylated arsenic species (MMA+DMA). The first and second balances (green boxes) point out 
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Context:  The role of arsenic metabolism in mortality remains unclear and relevant 
evidence is scarce.  
Objective:  To assess the prospective association between arsenic metabolism and all-
cause, cardiovascular, and cancer mortality in American Indian population exposed to 
low-moderate levels of arsenic 
Design, Setting, and Participants: Prospective cohort study in 3,600 American Indian 
participants aged 45 to 75 years living in Arizona, Oklahoma, and North and South 
Dakota. The sum of urine inorganic arsenic (arsenite and arsenate), monomethylated 
(MMA), and dimethylated (DMA) arsenic compounds at baseline was used as the 
biomarker of inorganic arsenic exposure from multiple sources. The proportions of urine 
inorganic arsenic (arsenite and arsenate, iAs), MMA and DMA over the sum of inorganic 
and methylated species, expressed as iAs%, MMA%, and DMA%, was used to evaluate 
arsenic metabolism. 
Main outcome measures:  All-cause, cardiovascular, and cancer mortality. Causes of 
death were determined by the Strong Heart Study Mortality Review Committee.  
Results: The median (interquartile range) for inorganic arsenic%, MMA% and DMA% 
was 8.0 (5.6 to 11.0), 14.0 (10.8 to 17.6) and 77.7 (71.9 to 82.6), respectively. The 
adjusted hazard ratio of all-cause mortality for an interquartile change increase in DMA% 
was 1.16 (95% CI 1.01-1.33) when it substituted iAs% whereas MMA% did not explain 
the risk of all-cause mortality. For cardiovascular mortality, the adjusted hazard ratio for 
an interquartile change increase in MMA% was 1.52 (1.16-1.99) and 1.17(1.01-1.35) 
when it substituted iAs% and DMA%, respectively. For cancer mortality, the adjusted 
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hazard ratio for an interquartile increase in MMA% was 0.73 (0.55-0.98) and 0.81 (0.67-
0.97) when it substituted iAs% and DMA%, respectively. 
Conclusion:  Different patterns of arsenic metabolism profile are significantly associated 
with all-cause, cardiovascular and cancer mortality and the effects  are independent of 
levels of arsenic exposure.  More experimental and epidemiological evidence are needed 





















Inorganic arsenic exposure is a major public health problem worldwide.1 Indeed, 
chronic exposure to inorganic arsenic through water and foods has been associated with 
diverse chronic diseases including various forms of cancer2, cardiovascular diseases3, 4, 
diabetes5, 6, and kidney dysfunction7 at a wide range of arsenic exposure levels.  
Chronic arsenic exposure has also been related to increased mortality, including 
all-cause8, cancer9, 10, and cardiovascular disease mortality10-13 in many parts of the world 
including Argentina, Bangladesh, Chile, Taiwan, and the USA. Most studies used arsenic 
concentrations in well water or individual urine total arsenic concentrations as primary 
exposure matrices. Few studies, however, have systematically evaluated the role of 
arsenic metabolism in all-cause and disease-specific mortality. In humans, the average 
distribution of arsenic metabolites in urine is 10-30% inorganic arsenic [iAs], 10-20% 
monomethylarsonate [MMA], and 60-80% dimethylarsinate [DMA], with substantial 
inter-individual variation.14, 15 Higher MMA% and lower DMA% in urine have been 
related to increased risk of various cancers16, 17 and cardiovascular diseases,18, 19 although 
some studies showed no or inconsistent association. In addition, recent studies have 
connected increased urine DMA% with increased prevalence of diabetes20 and 
adiposity.21 Possible mechanisms underlying a differential role for arsenic methylation 
patterns on disease outcomes could be related to one-carbon metabolism and methylation 
dysregulation.22, 23 Understanding how arsenic methylation capacity is associated with 
mortality risks and whether the association is different by cause of death could be useful 
to arsenic risk assessment as well as to increase our understanding of arsenic toxicity 
mechanisms.   
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In this study, we examined the association of arsenic exposure and arsenic 
metabolism with the risk of mortality, including all-cause, cardiovascular and cancer 
mortality, in the Strong Heart Study, a large population-based prospective cohort with 
almost 20 years of follow-up.12, 24 We also evaluated whether the association between 





The Strong Heart Study is a population-based cohort study that examined risk 
factors of cardiovascular mortality and morbidity in American Indians from Arizona, 
Oklahoma and North and South Dakota. Overall, 4549 men and women aged 45-74 years 
of age were enrolled between 1989 and 1991.24 All eligible individuals were invited to 
participate in Arizona and Oklahoma, whereas a cluster sampling procedure was applied 
in North and South Dakota.24, 25 The overall participation rate was 62%.25 The study 
population was stable during the follow-up period due to low migration rates and strong 
cultural and community links among SHS participants.26 Compared with nonparticipants, 
participants were similar in age, body mass index, and prevalence of self-reported 
diabetes but were more likely to be female and to have self-reported hypertension.25 The 
Indian Health Service, institutional review boards, and participating tribes approved the 
study protocol. All participants provided informed consent. 
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For this study, we used data from 3,973 participants with sufficient urine available 
for arsenic measurements at the baseline visit. We then excluded 228 participants with 
some arsenic species data (inorganic arsenic, MMA or DMA) below the limit of 
detection, as arsenic metabolism cannot be evaluated at undetectable arsenic exposure 
levels, 5 missing smoking status, 2 missing education, 8 missing alcohol drinking status, 
16 missing body mass index,  26 missing waist-hip ratio, 15 missing hypertension status, 
66 missing estimated glomerular filtration rate, and 7 missing baseline fasting glucose 
level, leaving 3,600 participants for this analysis. Included participants were similar to 
those who were excluded because of missing data (data not shown).   
Data collection 
Baseline clinical information included a personal interview, physical examination, 
fasting blood test, and spot urine sample collection.24 Socidemographic (age, sex, and 
education) and lifestyle (smoking and alcohol status) information was collected by 
trained and certified interviewers using standardized questionnaires.24 Physical 
examination measurements (height, weight, waist and hip circumferences, and systolic 
and diastolic pressures) and bio-specimen collection (blood and urine) were conducted by 
centrally trained nurses and medical assistants following a standardized protocol.24  
Detailed procedures of clinical and laboratory examinations have been published.24 
Participants were asked to fast for 12 hours before blood samples were collected in the 
morning, at baseline and in the two subsequent visits. Serum creatinine was measured by 
an alkaline-picrate rate method.24 Estimated glomerular filtration rate at baseline was 
derived from the 4-variable isotope dilution mass spectrometry Modification of Diet in 
Renal Disease Study equation.27 Spot urine samples were collected in the morning and 
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were frozen with 1 to 2 hours of collection. The biospecimens were stored at -70°C or 
lower before analyses.24 Urine creatinine and specific gravity levels were measured by an 
automated alkaline picrate method and Leica TS 400 total solid refractometer (Leica 
Microsystems, Buffalo, USA), respectively.24   
Urine arsenic measurements 
The urine concentrations of arsenic species in the Strong Heart Study population 
were stable over a 10-year follow up (between 1989-1991 and 1998-1999), reflecting 
population stability and the appropriateness of one single urine arsenic sample to 
represent long-term arsenic exposure.28 Detailed analytic methods and associated quality 
control procedures for arsenic analysis have been described.29 Arsenic species 
concentrations were determined by high-performance liquid chromatography (HPLC) 
coupled to inductively coupled plasma mass spectrometry (ICP-MS) that served as the 
arsenic selective detector (Agilent 1100 HPLC and Agilent 7700x ICP-MS, Agilent 
Technologies, Santa Clara, California). Arsenic speciation could discriminate species 
directly related to inorganic arsenic exposure (arsenite, arsenate, monomethylarsonate 
[MMA], and dimethylarsinate [DMA]) from those related to organic arsenicals in seafood 
(arsenobetaine as an overall marker of seafood arsenicals), which are generally 
considered nontoxic.30 The limit of detection (LOD) for total arsenic and for inorganic 
arsenic (arsenite plus arsenate), MMA, DMA, and arsenobetaine plus other arsenic 
cations was 0.1 μg/L. The percentages of participants with concentrations below the limit 
of detection were 0.03% for total arsenic, 5.2% for inorganic arsenic, 0.8% for MMA, 
0.03% for DMA, and 2.1% for arsenobetaine plus other arsenic cations. Levels of arsenic 
species below the limit of detection were replaced by the corresponding limit of detection 
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divided by the square root of 2. An in-house reference urine and the Japanese National 
Institute for Environmental Studies No. 18 Human Urine were analyzed together with the 
samples. Interassay coefficients of variation for total arsenic, inorganic arsenic, MMA, 
DMA and arsenobetaine plus other arsenic cations for the in-house reference urine were 
4.4%, 6.0%, 6.5%, 5.9%, and 6.5%, respectively. 
Arsenic exposure and arsenic metabolism 
We used the sum of urine inorganic arsenic (arsenite and arsenate) and methylated 
arsenic species (MMA and DMA) as the biomarker of inorganic arsenic exposure from 
multiple sources.31-33 Urine arsenic concentrations were divided by urine creatinine 
concentrations to account for urine dilution-concentration and expressed as μg/g 
creatinine.  Urine concentrations of arsenobetaine and other arsenic cations were very 
low (median, 0.68; interquartile range, 0.41 to 1.54 μg/g creatinine), confirming that 
seafood intake was low in this sample, and indicating that DMA mainly came from 
inorganic arsenic exposure.34  
To assess arsenic metabolism, we used the proportions of urine iAs (arsenite and 
arsenate), MMA and DMA over the sum of inorganic and methylated species, expressed 
as iAs%, MMA%, and DMA%, to evaluate arsenic metabolism. 
Mortality follow-up 
 Vital status and cause-of-death codes were determined through 2008 by annual 
contact, review of hospitalization records and death certificates, and information obtained 
from the National Death Index. Mortality follow up was complete in 99.8% of the study 
participants. Study participants were followed from the date of the baseline examination 
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until the date of death or 31 December 2008, whichever occurred first. Cause of death 
were classified using the International Classification of Diseases, Ninth Revision (ICD-9) 
and were grouped into 4 broad categories by the SHS Mortality Review Committee based 
on the standardized mortality surveillance procedures including discharge summary of 
the terminal hospital admission, medical reports, autopsy, and pathology report (if 
available): cardiovascular diseases, cancer, respiratory and infectious disease, and all 
other causes.  For cardiovascular disease deaths, the ascertainment of the specific cause 
of death was made through a central adjudication committee. Detailed definitions of the 
criteria used by the central adjudication committee have been described previously.35  
Statistical analyses 
 Urine concentrations of the sum of inorganic and methylated species were 
modeled as quartiles and as log-transformed concentrations, comparing an interquartile 
range. Arsenic metabolism (iAs%, MMA%, and DMA%) was modeled as continuous, 
comparing an interquartile range.  
We used Cox proportional hazards modeling to quantify the relative hazard of 
mortality associated with arsenic exposure and arsenic metabolism.36 The time scale for 
survival analysis was age, facilitating adjustment for this strong predictor of mortality. To 
handle left-truncation induced by time of enrollment and appropriately aligning risk sets 
on the age scale, the late entry method was conducted using individual entry time (age at 
baseline). All proportional hazards models were adjusted for study sites (using the 
stratified Cox procedure), education level (less than high school, some high school, high 
school or more), smoking status (never, former, current), alcohol drinking (never, former, 
current), body mass index (continuous), and waist-hip ratio (continuous). Although we 
60 
 
did not adjust for health conditions that could be in the causal pathway such as 
hypertension, and diabetes, we conducted stratified analysis to explore the consistency of 
the association between arsenic metabolism and mortality across levels of these 
comorbidities.  We will also examined whether the association between arsenic 
metabolism and risk of mortality varied by sex, smoking status, body mass index (<25, 
25-30, >30 kg/m2), abdominal obesity (defined by waist circumference >112 cm and >88 
cm for men and women, respectively).  
 All statistical analyses were performed in Stata/IC, version 12 (StataCorp, College 
Station, Texas) and with R, version 3.0.0 (R foundation for Statistical Computing, 




A total of 1,559 (43.3%) participants died of any cause over 51,810.3 person-
years of follow-up; 484(13.4 %) died of cardiovascular disease (CVD), and 281 (7.8%) 
died of cancer.  Overall, median concentration of the sum of inorganic and methylated 
arsenic species in the urine was 11.2 μg/L (interquartile range, 6.6 to 19.1 μg/L). Urine 
arsenic concentrations were higher in participants from Arizona (median 14.9 μg/L), 
followed by the Dakotas (12.6 μg/L) and Oklahoma (median 7.2 μg/L). The median 
(interquartile range) for iAs%, MMA% and DMA% was 8.0 (5.6 to 11.0)%, 14.0 (10.8 to 
17.6)% and 77.7 (71.9 to 82.6)%, respectively.  
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Arsenic exposure and all-cause and cause specific mortality 
Baseline urine concentrations of inorganic arsenic, methylated arsenic species 
including MMA and DMA, and the sum of inorganic and methylated arsenic species 
were significantly higher among participants who died during the follow-up (Table 1). 
The fully adjusted hazard ratios for all-cause mortality, CVD mortality, and cancer 
mortality were 1.28 (95% CI 1.16-1.41), 1.28 (1.08-1.52), and 1.15 (0.92-1.44), 
respectively, for an interquartile range increase in urine concentrations of the sum of 
inorganic and methylated arsenic species (Table 2).  
Arsenic metabolism and all-cause mortality 
 Before adjustment, baseline arsenic metabolism profiles were comparable 
between survivors and deceased participants (Table 1). When modeling each arsenic 
metabolism biomarker one at a time, each interquartile range increase in iAs%, MMA%, 
and DMA% were prospectively associated with all-cause mortality with hazard ratio 0.91 
(95%CI 0.85 -0.97), 0.91 (CI 0.85-0.98), and 1.12 (1.04-1.21) in fully adjusted models, 
respectively (Table 3, model 3). When modeling arsenic metabolism by including two 
biomarkers at the same time, the adjusted hazard ratio of mortality for an interquartile 
range increase in iAs% was 0.97 (95% CI 0.87-1.09) when it substituted MMA% and 
0.93 (0.87-0.99) when it substituted DMA%.   
The adjusted hazard ratio of mortality for an interquartile range increase in 
MMA% was 1.03 (95% CI 0.90-1.19) and 0.94 (0.87-1.03) when it substituted iAs% and 
DMA%, respectively. The adjusted hazard ratio of mortality for an interquartile range 
increase in DMA% was 1.16 (1.01-1.33) and 1.10 (0.96-1.25) when it substituted iAs% 
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and MMA%, respectively (Table 3, model 3). In dose-response analyses, increasing 
DMA% was related to increased all-cause mortality when it substituted both iAs% and 
MMA% (Figure 1). iAs% was associated with lower all-cause mortality when it 
substituted DMA% but not when it substituted MMA%.  The association between arsenic 
metabolism and all-cause mortality was stronger in participants with female gender, 
diabetes, and obesity. However, the association was similar across all arsenic exposure 
categories (Table 6).   
Arsenic metabolism and cardiovascular disease mortality 
 When including each arsenic metabolism biomarker in the multivariable Cox 
proportional hazards model one at a time, the fully adjusted hazard ratio of cardiovascular 
diseases (CVD) mortality for each interquartile range increase in iAs%, MMA%, and 
DMA% was 0.86 (95%CI 0.76 -0.97), 1.05 (CI 0.93-1.20), and 1.07 (0.94-1.21), 
respectively (Table 4, model 3). When modeling arsenic metabolism by including two 
biomarkers in the Cox regression model at the same time, the adjusted hazard ratio for an 
interquartile range increase in iAs% was 0.72 (95% CI 0.58-0.89) and 0.81 (0.71-0.93) 
when it substituted MMA% and DMA%, respectively.  The adjusted hazard ratio for an 
interquartile range increase in MMA% was 1.52 (95% CI 1.16-1.99) and 1.17 (1.01-1.35) 
when it substituted iAs% and DMA%, respectively. The adjusted hazard ratio for an 
interquartile range increase in DMA% was 1.53 (1.16-2.00) and 0.78 (0.63-0.98) when it 
substituted iAs% and MMA%, respectively (Table 4, model 3). In dose-response 
analyses, increasing MMA% was related to increased CVD mortality when it substituted 
both% inorganic arsenic and DMA% (Figure 2). DMA% was associated with increased 
CVD mortality when it substituted iAs% but not when it substituted MMA%.  The 
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association between arsenic metabolism and cardiovascular mortality was similar across 
all arsenic exposure categories (Table 7). 
Arsenic metabolism and cancer mortality 
 When including each arsenic metabolism biomarker in the modeling one at a 
time, the hazard ratio of cancer mortality for each interquartile range increase in iAs%, 
MMA%, and DMA% was 1.02 (95%CI 0.89 -1.17), 0.84 (CI 0.70-1.00), and 1.09 (0.92-
1.29) in full adjustment models, respectively (Table 5, model 3). When modeling arsenic 
metabolism by including two biomarkers in the Cox regression model at the same time, 
the adjusted hazard ratio for an interquartile range increase in iAs% was 1.28 (95% CI 
1.02-1.62) and 1.08 (0.95-1.24) when it substituted MMA% and DMA%, respectively.  
The adjusted hazard ratio for an interquartile range increase in MMA% was 0.73 (95% CI 
0.55-0.98) and 0.81 (0.67-0.97) when it substituted iAs% and DMA%, respectively. The 
adjusted hazard ratio for an interquartile range increase in DMA% was 0.85 (0.65-1.12) 
and 1.40 (1.04-1.87) when it substituted iAs% and MMA%, respectively (Table 5, model 
3). In dose-response analyses, increasing MMA% was related to lower cancer mortality 
when it substituted both% inorganic arsenic and DMA% (Figure 3). DMA% was 
associated with increased cancer mortality when it substituted MMA% but not when it 
substituted iAs%. The association between arsenic metabolism and cardiovascular 





Research on the role of arsenic metabolism in all-cause mortality and cause-
specific mortality is scarce. Our study is the first study to systematically examine the 
relationship between arsenic metabolism and mortality using data from a population-
based cohort. We found the substitution of iAs% by DMA% was prospectively associated 
with higher all-cause mortality. The substitution of iAs% by either MMA% or DMA% 
was associated with higher cardiovascular disease (CVD) mortality. The substitution of 
DMA% by MMA% was also related to higher CVD mortality. For cancer mortality, the 
substitution of MMA% by either iAs% or DMA% was prospectively associated with 
higher cancer mortality.  
The mechanism underlying the association between arsenic metabolism and all-
cause mortality remains unclear though many biological hypotheses have been raised.22  
One of the major hypothesis involves one carbon metabolism, which encompasses a 
tightly interconnected metabolic network by cycling carbon units from amino acid inputs 
to generate essential cellular outputs including biosynthesis, redox balance, and 
methylation reactions.37 The optimal balance between nutrition and one-carbon 
metabolism is critical to maintain genome stability, modulate epigenomics, and keep 
cellular homeostasis and detoxification. Metabolic imbalance from methylation 
dysregulation in one-carbon metabolism has been specially linked to the development of 
cancer, cardiovascular diseases, and diabetes, which could potentially explain the arsenic-
related pleiotropic adverse effect. To what extent arsenic interferes with one-carbon 
metabolism remains to be determined; however, inter-individual variation in arsenic 
methylation profile may reflect both differential individual susceptibility toward arsenic 
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exposure and differential metabolic capacity to maintain methyl balance, the fundamental 
driver of various downstream physiologic reactions.38 Increasing evidence has shown that 
nutrition (e.g. folic acid supplementation) can play a role in mitigating arsenic toxicity.39 
Arsenic exposure has also been associated with global DNA methylation in a number of 
studies, although studies targeting on arsenic metabolism and epigenomic patterns is 
limited.40-42 Our findings will motivate experimental and clinical research to investigate 
the biological mechanisms and potential interventions for adjusting arsenic metabolism in 
risk modification and risk reduction in arsenic-related health problems.  
Strengths of the current study include careful modeling of the dynamic of arsenic 
metabolism, standardized protocol to ascertain mortality data over a 20-year follow-up 
and high-quality laboratory methods for measuring concentrations of urine arsenic 
species. This study had several limitations. First, the urine arsenic concentrations and 
metabolism were measured in a single sample at baseline to represent internal doses and 
individual metabolism profiles. However, we have confirmed that arsenic levels in urine 
and arsenic metabolism were constant over 10 years in this population.28 Second, over-
adjustment for variables that possibly in the cause pathway (e.g. HbA1c and fasting 
glucose in all-cause mortality) could not be excluded. However, multiple sensitively 
analyses yielded consistent results. Third, it is possible that unknown and unmeasured 
confounding may bias our findings. For example, we do not have all possible 
measurements of human exposure to environmental toxicants that may modify both 
arsenic metabolism profiles and risk of mortality. Finally, given the observational nature 
of this study, we cannot firmly conclude that the association between arsenic metabolism 





This is the first study to show that specific profiles of arsenic metabolism are 
associated with all-cause, cardiovascular disease, and cancer mortality. The patterns were 
different for cardiovascular and cancer mortality. Understanding the differential 
individual susceptibility measured by arsenic metabolism to the risk of mortality can be 
critical in risk assessment of arsenic toxicity. Additional experimental and 
epidemiological evidence are needed to understand the biological reasons and clinical 











  N (%) Median(IQR) N %  Median(IQR)  
Age, year    52.7 (48.3‐58.7)    58.3 (51.4‐65.5)  <0.01 
Male  756 (37.0)    740 (47.5)    <0.01 
Location          <0.01 
  Arizona  633 (31.0)    630 (40.4)     
  Oklahoma  747 (36.6)    370 (23.7)     
  North and South Dakota  661 (32.4)    559 (35.9)     
Education (yrs)          <0.01 
  No high school  333 (16.3)    484 (31.1)     
  Some high school  456 (22.3)    429 (27.5)     
  High school or more  1252 (61.3)    646 (41.4)     
Smoking (%)          0.44 
  Never  669 (32.8)    485 (31.1)     
  Former  691 (33.9)    525 (33.7)     
  Current  681 (33.4)    549 (35.2)     
Alcohol (%)          0.25 
  Never  310 (15.2)    255 (16.4)     
  Former  868 (42.5)    621 (39.8)     
  Current  863 (42.3)    683 (43.8)     
Body mass index    30.4 (27.1‐34.6)     29.7 (26.0‐33.9)  <0.01 
Waist‐hip ratio    0.95 (0.91‐0.98)    0.96 (0.93‐1.00)  <0.01 
Waist circumference (cm)    104 (96‐115)    104 (95‐114)  0.81 
% Body fat    37.8 (30.4‐43.9)    34.5 (28.2‐42)  <0.01 
Urine creatinine, g/L    1.28 (0.83‐1.79)    1.11 (0.73‐1.61)  <0.01 
Specific gravity    1.02 (1.015‐1.024)    1.018 (1.014‐1.023)  0.27 
eGFR , ml/min/1.73m2    81.9 (72.7‐94.1)    80.7 (68.0‐93.7)  <0.01 
Hypertension  616 (30.2)    754 (48.4)    <0.01 
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Diabetes mellitus  807 (39.5)    959 (61.5)    <0.01 
Fasting glucose, mg/dL    110 (98‐142)    129 (103‐218)  <0.01 
HbA1c, %  N=1,922  5.4 (4.9‐6.6)    6.1 (5.1‐9.2)  <0.01 
Arsenic exposure            
iAs + methylated arsenic*, g/g    8.9 (5.6‐14.2)    11.9 (7.1‐18.4)  <0.01 
iAs, g/g    0.7 (0.4‐1.3)    0.9 (0.4‐1.7)  <0.01 
MMA, g/g    1.2 (0.7‐2.0)    1.6 (0.9‐2.7)  <0.01 
DMA, g/g    6.7 (4.2‐11.0)    9.1 (5.4‐14.2)  <0.01 
Arsenic metabolism           
iAs%    8.0 (5.6‐11.0)    7.9 (5.6‐11.0)  0.37 
MMA%    13.9 (11.0 ‐17.4)    14.1 (10.6‐17.8)  0.59 






















All‐cause mortality      N=3,404  N=3,404  N=3,404 
iAs (0.4‐1.7 μg/L)  1.08 (0.99‐1.18)  1.03 (0.94‐1.13)  1.06 (0.97‐1.17)  1.07 (0.99‐1.17)  0.97 (0.89‐1.05) 
MMA ( 0.8‐2.8 μg/L)  1.15 (1.05‐1.26)  1.12 (1.02‐1.24)  1.11 (1.00‐1.22)  1.08 (0.99‐1.17)  0.96 (0.89‐1.04) 
DMA ( 5.1‐14.5 μg/L)  1.35 (1.23‐1.47)  1.31 (1.19‐1.43)  1.29 (1.18‐1.42)  1.19 (1.11‐1.29)  1.04 (0.97‐1.12) 
iAs + methylated arsenic (6.6‐19.1 μg/L)  1.33 (1.21‐1.45)  1.28 (1.17‐1.40)  1.28 (1.16‐1.41)  1.18 (1.09‐1.28)  1.03 (0.96‐1.12) 
Cardiovascular disease (CVD)  mortality      N=3,542  N=3,542  N=3,542 
iAs (0.4‐1.7 μg/L)  0.97 (0.83‐1.13)  0.94 (0.80‐1.11)  1.02 (0.86‐1.20)  0.93 (0.81‐1.08)  0.88 (0.75‐1.02) 
MMA ( 0.8‐2.8 μg/L)  1.20 (1.02‐1.42)  1.21 (1.02‐1.43)  1.25 (1.05‐1.49)  1.02 (0.89‐1.17)  0.96 (0.83‐1.10) 
DMA ( 5.1‐14.5 μg/L)  1.34 (1.15‐1.57)  1.36 (1.16‐1.60)  1.28 (1.08‐1.51)  1.02 (0.89‐1.16)  0.96 (0.84‐1.09) 
iAs + methylated arsenic (6.6‐19.1 μg/L)  1.31 (1.11‐1.55)  1.29 (1.09‐1.52)  1.28 (1.08‐1.52)  1.02 (0.89‐1.17)  0.95 (0.83‐1.09) 
Cancer mortality      N=3,571  N=3,571  N=3,571 
iAs (0.4‐1.7 μg/L)  1.15 (0.94‐1.41)  1.12 (0.91‐1.38)  1.13 (0.91‐1.39)  1.14 (0.95‐1.37)  1.03 (0.85‐1.25) 
MMA ( 0.8‐2.8 μg/L)  1.02 (0.82‐1.27)  0.98 (0.79‐1.23)  0.99 (0.79‐1.24)  1.01 (0.84‐1.21)  0.91 (0.76‐1.09) 
DMA ( 5.1‐14.5 μg/L)  1.17 (0.95‐1.44)  1.18 (0.95‐1.46)  1.17 (0.95‐1.45)  1.14 (0.96‐1.36)  1.00 (0.85‐1.18) 


























One metabolism biomarker in each model           
iAs%  0.89 (0.83‐0.95)  0.87 (0.82‐0.93)  0.91 (0.85‐0.97)  0.95 (0.89‐1.01)  0.96 (0.90‐1.02) 
MMA%  0.91 (0.85‐0.98)  0.90 (0.84‐0.97)  0.91 (0.85‐0.98)  0.91 (0.84‐0.98)  0.90 (0.84‐0.97) 
DMA%  1.14 (1.07‐1.22)  1.17(1.09‐1.25)  1.12 (1.04‐1.21)  1.09 (1.02‐1.18)  1.09 (1.01‐1.17) 
Two metabolism biomarker in each model           
iAs% substituted by:           
  MMA%  (10.8‐17.6)  1.08 (0.94‐1.24)  1.10 (0.95‐1.26)  1.03 (0.90‐1.19)  0.95 (0.83‐1.09)  0.91 (0.80‐1.05) 
  DMA%   (71.9‐82.6)  1.22 (1.07‐1.40)  1.26 (1.10‐1.45)  1.16 (1.01‐1.33)  1.05 (0.92‐1.20)  1.01 (0.89‐1.16) 
MMA% substituted by:           
  iAs%       (5.6‐11.0)  0.94 (0.84‐1.05)  0.93 (0.83‐1.04)  0.97 (0.87‐1.09)  1.04 (0.93‐1.16)  1.07 (0.96‐1.20) 
  DMA%   (71.9‐82.6)  1.08 (0.95‐1.22)  1.09 (0.96‐1.24)  1.10 (0.96‐1.25)  1.14 (1.00‐1.30)  1.17 (1.03‐1.33) 
DMA% substituted by:           
  iAs%       (5.6‐11.0)  0.90 (0.84‐0.97)  0.89 (0.83‐0.95)  0.93 (0.87‐0.99)  0.98 (0.91‐1.04)  0.99 (0.93‐1.06) 



































One metabolism biomarker in each model           
iAs%  0.79 (0.70‐0.89)  0.78 (0.69‐0.88)  0.86 (0.76‐0.97)  0.94 (0.83‐1.05)  0.93 (0.83‐1.05) 
MMA%  0.97 (0.86‐1.10)  1.00 (0.88‐1.14)  1.05 (0.93‐1.20)  1.05 (0.92‐1.19)  1.04 (0.92‐1.19) 
DMA%  1.18 (1.04‐1.33)  1.17 (1.03‐1.33)  1.07 (0.94‐1.21)  1.02 (0.89‐1.15)  1.02 (0.90‐1.16) 
Two metabolism biomarker in each model           
iAs% substituted by:           
  MMA%  (10.8‐17.6)  1.57 (1.22‐2.04)  1.67 (1.29‐2.18)  1.52 (1.16‐1.99)  1.26 (0.97‐1.64)  1.25 (0.96‐1.63) 
  DMA%   (71.9‐82.6)  1.75 (1.34‐2.29)  1.82 (1.39‐2.39)  1.53 (1.16‐2.00)  1.23 (0.95‐1.61)  1.23 (0.95‐1.60) 
MMA% substituted by:           
  iAs%       (5.6‐11.0)  0.70 (0.57‐0.86)  0.66 (0.54‐0.82)  0.72 (0.58‐0.89)  0.83 (0.67‐1.03)  0.86 (0.69‐1.08) 
  DMA%   (71.9‐82.6)  0.85 (0.69‐1.06)  0.81 (0.65‐1.01)  0.78 (0.63‐0.98)  0.86 (0.68‐1.08)  0.84 (0.68‐1.03) 
DMA% substituted by:           
  iAs%       (5.6‐11.0)  0.75 (0.66‐0.86)  0.74 (0.65‐0.85)  0.81 (0.71‐0.93)  0.90 (0.79‐1.03)  0.90 (0.79‐1.03) 



































One metabolism biomarker in each model           
iAs%  1.04 (0.92‐1.19)  1.01 (0.88‐1.16)  1.02 (0.89‐1.17)  1.05 (0.92‐1.20)  1.06 (0.93‐1.21) 
MMA%  0.88 (0.75‐1.04)  0.83 (0.70‐0.99)  0.84 (0.70‐1.00)  0.84 (0.70‐1.00)  0.83 (0.70‐0.99) 
DMA%  1.05 (0.89‐1.23)  1.10 (0.93‐1.31)  1.09 (0.92‐1.29)  1.07 (0.90‐1.26)  1.07 (0.90‐1.26) 
Two metabolism biomarker in each model           
iAs% substituted by:           
  MMA%  (10.8‐17.6)  0.76 (0.57‐1.00)  0.73 (0.55‐0.98)  0.73 (0.55‐0.98)  0.70 (0.53‐0.92)  0.68 (0.52‐0.90) 
  DMA%   (71.9‐82.6)  0.84 (0.65‐1.09)  0.86 (0.66‐1.13)  0.85 (0.65‐1.12)  0.81 (0.63‐1.05)  0.79 (0.62‐1.02) 
MMA% substituted by:           
  iAs%       (5.6‐11.0)  1.25 (1.00‐1.55)  1.28 (1.02‐1.61)  1.28 (1.02‐1.62)  1.33 (1.07‐1.66)  1.35 (1.09‐1.68) 
  DMA%   (71.9‐82.6)  1.30 (0.99‐1.72)  1.41 (1.06‐1.89)  1.40 (1.04‐1.87)  1.43 (1.07‐1.91)  1.45 (1.09‐1.94) 
DMA% substituted by:           
  iAs%       (5.6‐11.0)  1.09 (0.96‐1.24)  1.08 (0.94‐1.23)  1.08 (0.95‐1.24)  1.11 (0.98‐1.26)  1.12 (0.99‐1.27) 





























    MMA%  DMA%  iAs%  DMA%  iAs%  MMA% 
Age (years)               
  < 55  1723  0.98 (0.77‐1.25)  1.23 (0.97‐1.55)  1.02 (0.84‐1.23)  1.26 (1.01‐1.58)  0.90 (0.80‐1.02)  0.86 (0.75‐0.99) 
  ≥ 55   1681  1.05 (0.89‐1.25)  1.09 (0.92‐1.30)  0.96 (0.84‐1.10)  1.01 (0.86‐1.18)  0.96 (0.88‐1.04)  1.00 (0.90‐1.10) 
p‐value for interaction    0.71  0.69  0.71  0.82  0.69  0.82 
Sex               
  Men   1423  0.95 (0.79‐1.15)  1.02 (0.85‐1.21)  1.04 (0.90‐1.21)  1.10 (0.93‐1.32)  0.99 (0.91‐1.08)  0.94 (0.84‐1.05) 
  Women  1981  1.27 (1.00‐1.18)  1.52 (1.18‐1.96)  0.83 (0.68‐1.00)  1.05 (0.86‐1.28)  0.81 (0.71‐0.92)  0.97 (0.86‐1.10) 
p‐value for interaction    <0.01  <0.01  <0.01  0.22  <0.01  0.22 
Study site               
  Arizona  1230  1.23 (0.95‐1.59)  1.43 (1.11‐1.83)  0.85 (0.69‐1.04)  1.03 (0.82‐1.28)  0.84 (0.74‐0.95)  0.98 (0.86‐1.13) 
  Oklahoma   1023  0.92 (0.66‐1.28)  0.96 (0.69‐1.34)  1.07 (0.82‐1.39)  1.10 (0.83‐1.46)  1.02 (0.86‐1.20)  0.94 (0.79‐1.13) 
  North/South Dekota  1151  0.95 (0.77‐1.16)  1.08 (0.89‐1.30)  1.05 (0.89‐1.23)  1.17 (0.96‐1.44)  0.96 (0.88‐1.06)  0.90 (0.79‐1.03) 
p‐value for interaction    0.04  0.08  0.04  0.13  0.08  0.13 
Smoking               
  Never  1098  0.88 (0.70‐1.09)  0.97 (0.79‐1.19)  1.11 (0.93‐1.32)  1.19 (0.94‐1.52)  1.02 (0.92‐1.13)  0.89 (0.77‐1.04) 
  Former  1151  1.28 (0.98‐1.69)  1.47 (1.11‐1.94)  0.82 (0.66‐1.02)  0.99 (0.78‐1.25)  0.82 (0.72‐0.95)  1.01 (0.87‐1.17) 
  Current  1155  1.03 (0.81‐1.31)  1.16 (0.93‐1.46)  0.98 (0.81‐1.19)  1.11 (0.89‐1.39)  0.93 (0.83‐1.04)  0.93 (0.81‐1.07) 
p‐value for interaction    0.52  0.18  0.52  0.99  0.18  0.99 
DM               
  No  1722  0.78 (0.65‐0.96)  0.90 (0.74‐1.09)  1.21 (1.03‐1.41)  1.30 (1.07‐1.58)  1.06 (0.96‐1.16)  0.85 (0.75‐0.96) 
  Yes  1682  1.36 (1.11‐1.67)  1.50 (1.22‐1.83)  0.78 (0.67‐0.92)  0.92 (0.77‐1.09)  0.82 (0.74‐0.90)  1.06 (0.94‐1.18) 
p‐value for interaction    <0.01  <0.01  <0.01  <0.01  <0.01  <0.01 
Hypertension               
  No  1702  0.92 (0.75‐1.12)  1.05 (0.87‐1.26)  1.07 (0.92‐1.26)  1.21 (0.99‐1.48)  0.98 (0.89‐1.07)  0.89 (0.78‐1.01) 
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  Yes  1675  1.11 (0.90‐1.35)  1.21 (0.99‐1.48)  0.92 (0.79‐1.08)  1.03 (0.87‐1.22)  0.91 (0.82‐1.01)  0.98 (0.88‐1.09) 
p‐value for interaction    0.13  0.15  0.13  0.26  0.15  0.26 
Obesity               
  BMI< 30 kg/m2  1678  0.92 (0.78‐1.08)  1.01 (0.86‐1.18)  1.07 (0.94‐1.22)  1.16 (0.98‐1.36)  1.00 (0.92‐1.08)  0.91 (0.82‐1.01) 
  BMI≥ 30  1726  1.32 (1.02‐1.70)  1.55 (1.20‐2.00)  0.80 (0.66‐0.98)  1.00 (0.81‐1.24)  0.80 (0.71‐0.91)  1.00 (0.87‐1.14) 
p‐value for interaction    0.04  <0.01  0.04  0.70  <0.01  0.70 
Waist‐hip ratio               
  Non‐abdominal obesity*  953  0.83 (0.67‐1.04)  0.89 (0.73‐1.09)  1.16 (0.97‐1.37)  1.18 (0.96‐1.46)  1.06 (0.96‐1.17)  0.90 (0.79‐1.03) 
  Abdominal obesity  2451  1.25 (1.02‐1.52)  1.45 (1.19‐1.78)  0.84 (0.72‐0.98)  1.02 (0.87‐1.21)  0.83 (0.75‐0.92)  0.99 (0.89‐1.10) 
p‐value for interaction    <0.01  <0.01  <0.01  0.21  <0.01  0.21 
iAs+MMA+DMA               
 5.5 g/g   845  1.27 (0.84‐1.91)  1.27 (0.82‐1.98)  0.83 (0.60‐1.14)  0.87 (0.64‐1.19)  0.89 (0.71‐1.10)  1.09 (0.90‐1.32) 
> 5.5 &  8.8 g/g   842  1.25 (0.90‐1.73)  1.28 (0.92‐1.77)  0.84 (0.65‐1.08)  0.89 (0.68‐1.18)  0.89 (0.75‐1.04)  1.07 (0.90‐1.28) 
>8.8 &  13.9 g/g   850  0.80 (0.61‐1.06)  1.04 (0.81‐1.34)  1.19 (0.96‐1.48)  1.47 (1.13‐1.93)  0.98 (0.86‐1.11)  0.78 (0.66‐0.93) 
> 13.9 g/g   867  0.99 (0.79‐1.25)  1.17 (0.93‐1.45)  1.00 (0.84‐1.21)  1.18 (0.94‐1.48)  0.93 (0.83‐1.03)  0.90 (0.78‐1.04) 
p‐value for interaction    0.17  0.41  0.17  0.18  0.41  0.18 




















    MMA%  DMA%  iAs%  DMA%  iAs%  MMA% 
Age (years)               
  < 55  1780  1.62 (1.05‐2.50)  1.72 (1.10‐2.70)  0.68 (0.48‐0.96)  0.80 (0.55‐1.16)  0.76 (0.61‐0.95)  1.15 (0.91‐1.45) 
  ≥ 55   1762  1.45 (1.04‐2.03)  1.42 (1.01‐1.99)  0.74 (0.57‐0.97)  0.79 (0.59‐1.04)  0.84 (0.71‐0.99)  1.16 (0.97‐1.39) 
p‐value for interaction    0.56  0.51  0.56  0.75  0.51  0.75 
Sex               
  Men   1470  1.46 (1.00‐2.12)  1.37 (0.96‐1.97)  0.74 (0.55‐1.00)  0.75 (0.55‐1.04)  0.85 (0.71‐1.02)  1.19 (0.98‐1.46) 
  Women  2072  1.91 (1.27‐2.86)  2.05 (1.31‐3.20)  0.60 (0.43‐0.83)  0.74 (0.53‐1.03)  0.70 (0.56‐0.87)  1.21 (0.98‐1.50) 
p‐value for interaction    0.27  0.21  0.27  0.61  0.21  0.61 
Study site               
  Arizona  1241  1.98 (1.30‐3.03)  2.18 (1.37‐3.49)  0.58 (0.41‐0.81)  0.74 (0.52‐1.05)  0.68 (0.53‐0.86)  1.21 (0.97‐1.51) 
  Oklahoma   1095  1.47 (0.81‐2.64)  1.39 (0.75‐2.56)  0.74 (0.46‐1.18)  0.76 (0.47‐1.21)  0.85 (0.62‐1.15)  1.19 (0.89‐1.61) 
  North/South Dekota  1206  1.16 (0.79‐1.70)  1.18 (0.82‐1.68)  0.89 (0.66‐1.20)  0.93 (0.65‐1.34)  0.92 (0.77‐1.10)  1.05 (0.83‐1.32) 
p‐value for interaction    0.02  0.03  0.02  0.10  0.03  0.10 
Smoking               
  Never  1136  1.28 (0.84‐1.96)  1.27 (0.82‐1.95)  0.82 (0.59‐1.15)  0.85 (0.57‐1.26)  0.89 (0.72‐1.10)  1.11 (0.86‐1.42) 
  Former  1194  2.46 (1.46‐4.12)  2.20 (1.28‐3.79)  0.49 (0.32‐0.74)  0.53 (0.36‐0.80)  0.67 (0.51‐0.88)  1.49 (1.16‐1.92) 
  Current  1212  1.17 (0.75‐1.83)  1.36 (0.88‐2.09)  0.88 (0.62‐1.26)  1.06 (0.71‐1.57)  0.86 (0.69‐1.06)  0.97 (0.75‐1.24) 
p‐value for interaction    0.11  0.13  0.11  0.17  0.13  0.17 
Hypertension               
  No   1791  1.42 (0.95‐2.13)  1.28 (0.88‐2.13)  0.76 (0.55‐1.04)  0.74 (0.50‐1.08)  0.88 (0.73‐1.07)  1.21 (0.95‐1.55) 
  Yes  1751  1.69 (1.20‐2.38)  1.83 (1.27‐2.63)  0.66 (0.50‐0.86)  0.80 (0.60‐1.05)  0.74 (0.62‐0.89)  1.15 (0.97‐1.37) 
p‐value for interaction    0.16  0.04  0.16  0.83  0.04  0.83 
Obesity               
  BMI< 30 kg/m2  1743  1.29 (0.92‐1.82)  1.26 (0.90‐1.76)  0.82 (0.62‐1.07)  0.84 (0.61‐1.14)  0.89 (0.75‐1.06)  1.12 (0.92‐1.36) 
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  BMI≥ 30  1799  1.83 (1.20‐2.80)  1.87 (1.21‐2.91)  0.62 (0.44‐0.87)  0.72 (0.51‐1.01)  0.73 (0.59‐0.91)  1.23 (0.99‐1.53) 
p‐value for interaction    0.29  0.20  0.29  0.66  0.20  0.66 
Waist‐hip ratio               
  Non‐abdominal obesity*  997  1.14 (0.71‐1.82)  1.11 (0.71‐1.74)  0.90 (0.62‐1.31)  0.91 (0.60‐1.36)  0.95 (0.76‐1.19)  1.06 (0.82‐1.38) 
  Abdominal obesity  2545  1.73 (1.24‐2.42)  1.78 (1.25‐2.53)  0.65 (0.50‐0.84)  0.75 (0.57‐0.98)  0.75 (0.63‐0.89)  1.20 (1.01‐1.43) 
p‐value for interaction    0.17  0.14  0.17  0.40  0.14  0.40 
iAs+MMA+DMA               
 5.5 g/g   884  1.40 (0.72‐2.72)  1.21 (0.58‐2.51)  0.77 (0.45‐1.30)  0.71 (0.44‐1.16)  0.91 (0.63‐1.31)  1.24 (0.91‐1.69) 
> 5.5 &  8.8 g/g   888  1.12 (0.64‐1.95)  1.15 (0.66‐2.02)  0.91 (0.59‐1.42)  0.97 (0.59‐1.58)  0.93 (0.70‐1.23)  1.02 (0.75‐1.39) 
>8.8 &  13.9 g/g   887  1.36 (0.79‐2.35)  1.52 (0.92‐2.52)  0.78 (0.51‐1.20)  0.93 (0.56‐1.53)  0.81 (0.63‐1.04)  1.05 (0.76‐1.43) 
> 13.9 g/g  883  1.98 (1.26‐3.11)  2.11 (1.29‐3.44)  0.58 (0.41‐0.83)  0.72 (0.49‐1.05)  0.69 (0.54‐0.88)  1.23 (0.97‐1.57) 
p‐value for interaction    0.36  0.25  0.36  0.78  0.25  0.78 






















    MMA%  DMA%  iAs%  DMA%  iAs%  MMA% 
Age (years)               
  < 55  1796  0.73 (0.41‐1.30)  0.95 (0.55‐1.63)  1.28 (0.81‐2.01)  1.55 (0.89‐2.68)  1.03 (0.78‐1.35)  0.76 (0.54‐1.07) 
  ≥ 55   1775  0.72 (0.52‐1.00)  0.80 (0.59‐1.09)  1.30 (1.00‐1.69)  1.35 (0.96‐1.90)  1.12 (0.96‐1.30)  0.83 (0.67‐1.03) 
p‐value for interaction    0.62  0.99  0.62  0.44  0.99  0.44 
Sex               
  Men   1483  0.70 (0.47‐1.05)  0.86 (0.59‐1.25)  1.33 (0.96‐1.83)  1.51 (1.01‐2.27)  1.08 (0.89‐1.30)  0.77 (0.60‐0.99) 
  Women  2088  0.78 (0.50‐1.21)  0.87 (0.57‐1.34)  1.22 (0.86‐1.73)  1.29 (0.84‐1.99)  1.07 (0.86‐1.33)  0.85 (0.65‐1.12) 
p‐value for interaction    0.60  0.71  0.60  0.64  0.71  0.64 
Study site               
  Arizona  1252  0.84 (0.44‐1.63)  0.93 (0.50‐1.73)  1.14 (0.68‐1.93)  1.22 (0.67‐2.20)  1.04 (0.76‐1.42)  0.88 (0.61‐1.29) 
  Oklahoma   1104  0.69 (0.34‐1.40)  0.87 (0.43‐1.78)  1.34 (0.77‐2.35)  1.57 (0.84‐2.93)  1.07 (0.75‐1.54)  0.75 (0.51‐1.12) 
  North/South Dekota  1215  0.75 (0.52‐1.10)  0.90 (0.64‐1.27)  1.25 (0.93‐1.69)  1.41 (0.93‐2.13)  1.05 (0.89‐1.25)  0.81 (0.62‐1.05) 
p‐value for interaction    0.87  0.83  0.87  0.83  0.83  0.83 
Smoking               
  Never  1144  0.69 (0.42‐1.12)  0.70 (0.46‐1.07)  1.35 (0.91‐1.99)  1.27 (0.71‐2.28)  1.20 (0.97‐1.48)  0.86 (0.59‐1.24) 
  Former  1204  0.87 (0.47‐1.59)  1.00 (0.56‐1.80)  1.12 (0.69‐1.81)  1.26 (0.72‐2.20)  1.00 (0.74‐1.34)  0.87 (0.61‐1.23) 
  Current  1223  0.83 (0.53‐1.29)  0.97 (0.64‐1.48)  1.16 (0.81‐1.65)  1.31 (0.85‐2.01)  1.01 (0.82‐1.25)  0.84 (0.64‐1.11) 
p‐value for interaction    0.79  0.61  0.79  0.72  0.61  0.72 
DM               
  No  1819  0.60 (0.41‐0.87)  0.73 (0.51‐1.04)  1.51 (1.12‐2.03)  1.65 (1.12‐2.42)  1.17 (0.98‐1.41)  0.73 (0.57‐0.93) 
  Yes  1752  0.94 (0.58‐1.54)  1.06 (0.67‐1.69)  1.05 (0.71‐1.54)  1.16 (0.73‐1.84)  0.97 (0.77‐1.22)  0.91 (0.68‐1.22) 
p‐value for interaction    0.12  0.16  0.12  0.24  0.16  0.24 
Obesity               
  BMI< 30 kg/m2  1756  0.70 (0.50‐0.97)  0.85 (0.63‐1.15)  1.33 (1.02‐1.73)  1.50 (1.04‐2.15)  1.08 (0.93‐1.26)  0.77 (0.62‐0.97) 
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  BMI≥ 30 kg/m2  1815  0.97 (0.57‐1.67)  1.02 (0.60‐1.73)  1.02 (0.67‐1.57)  1.06 (0.66‐1.71)  0.99 (0.76‐1.29)  0.96 (0.71‐1.30) 
p‐value for interaction    0.15  0.19  0.15  0.28  0.19  0.28 
Waist‐hip ratio               
  Non‐abdominal obesity*  1002  0.68 (0.43‐1.06)  0.75 (0.50‐1.14)  1.36 (0.95‐1.95)  1.39 (0.90‐2.17)  1.15 (0.94‐1.42)  0.81 (0.61‐1.07) 
  Abdominal obesity  2569  0.87 (0.59‐1.30)  0.99 (0.67‐1.46)  1.11 (0.81‐1.53)  1.22 (0.84‐1.78)  1.01 (0.83‐1.23)  0.88 (0.69‐1.12) 
p‐value for interaction    0.18  0.12  0.18  0.48  0.12  0.48 
iAs+MMA+DMA               
 5.5 g/g    897  0.78 (0.34‐1.81)  0.81 (0.34‐1.94)  1.22 (0.62‐2.38)  1.21 (0.63‐2.33)  1.11 (0.72‐1.71)  0.89 (0.59‐1.34) 
> 5.5 &  8.8 g/g   891  1.10 (0.52‐2.35)  1.15 (0.53‐2.51)  0.92 (0.51‐1.69)  0.98 (0.52‐1.87)  0.93 (0.63‐1.38)  1.01 (0.67‐1.51) 
>8.8 &  13.9 g/g   893  0.51 (0.32‐0.81)  0.68 (0.46‐0.99)  1.70 (1.18‐2.46)  1.95 (1.13‐3.38)  1.22 (1.01‐1.47)  0.65 (0.46‐0.93) 
> 13.9 g/g   890  0.90 (0.51‐1.60)  1.03 (0.60‐1.76)  1.08 (0.69‐1.71)  1.21 (0.69‐2.12)  0.99 (0.75‐1.29)  0.89 (0.62‐1.27) 
p‐value for interaction    0.40  0.51  0.40  0.58  0.50  0.58 
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Little is known regarding arsenic metabolism in diabetes development.  We investigated 
the prospective associations of low-moderate arsenic exposure and arsenic metabolism 
with diabetes incidence in the Strong Heart Study. 
Research Design and Methods 
A total of 1,694 diabetes-free participants aged 45-75 years were recruited in 1989-1991 
and followed through 1998-1999. We used the proportions of urine inorganic 
arsenic(iAs), monomethylated(MMA), and dimethylated(DMA) over their sum 
(expressed as iAs%, MMA%, and DMA%) as the biomarkers of arsenic metabolism. 
Diabetes was defined as fasting glucose ≥126 mg/dL, 2–h glucose ≥200 mg/dL, self-
reported diabetes history, and self-reported use of anti-diabetic medications. 
Results 
Over 11,263.2 person-years of follow-up, 396 participants developed diabetes. Using the 
leave-one-out approach to model the dynamics of arsenic metabolism, we found 
increasing MMA% was associated with decreased diabetes incidence. The hazard ratios 
(95% CI) of diabetes incidence for an IQR change in MMA% were 0.69 (0.52, 0.90) and 
0.76 (0.65, 0.89) when iAs% and DMA% were, respectively, left-out of the model. 
DMA% was associated with increased diabetes incidence only when MMA% decreased 
(left-out from the model), but not when iAs% decreased. iAs% was also associated with 
increased diabetes incidence when MMA% decreased. The association between MMA% 
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and diabetes incidence was similar by age, sex, study site, obesity, and arsenic exposure 
status. 
Conclusions 
Arsenic metabolism, in particular lower MMA%, was prospectively associated with 
increased incidence of diabetes. Research is needed to evaluate whether arsenic 
metabolism is related to diabetes incidence per se, or through its close connections with 















Humans are exposed to inorganic arsenic through drinking water, food, dust, and 
ambient air.1 Increasing epidemiologic and experimental evidence supports a role for 
inorganic arsenic in the development of diabetes mellitus.2, 3 At high arsenic levels (>150 
µg/L in drinking water), evidence from Taiwan and Bangladesh supports an association 
with diabetes, although most studies are cross-sectional and there are concerns about 
measures of arsenic exposure and the definition of diabetes in some studies.2, 4 At low-
moderate arsenic levels, recent evidence from Mexico and the United states, including 
cross-sectional5, 6 and prospective studies7, 8 support the role of arsenic in diabetes 
development.  
Little is known, however, about the association between arsenic metabolism and 
diabetes. After absorption, inorganic arsenic (iAs; arsenate and arsenite) is methylated, 
primarily in the liver, to form monomethylated (MMA) and dimethylated (DMA) arsenic 
compounds, which are excreted into the urine together with iAs.9, 10 Higher MMA% and 
lower DMA% in urine have been related to increased risk of cancer11-13 and 
cardiovascular disease in studies from Taiwan and Bangladesh.14, 15 The increased risk of 
cancer and cardiovascular disease associated with higher MMA% in urine may be related 
to the high toxicity of MMA (III).16, 17 DMA is regarded as a less toxic arsenic species, as 
DMA is more rapidly excreted through the urine compared to inorganic arsenic.18, 19 
DMA (III), however, has been recently linked to the prevalence of diabetes in cross-
sectional studies from Mexico and Bangladesh.5, 20 Higher DMA% and lower MMA% 
has also been related to obesity in studies from Mexico and the US,21, 22 although the 
temporality of these associations is unclear. In addition, arsenic metabolism is tightly 
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connected with one-carbon metabolism,23 which has been implicated in both cancer 
development and cardiovascular disease,24, 25 and may also play a role in diabetes.26, 27 
These findings highlight the need to properly evaluate the role of arsenic methylation 
profiles in diabetes development.   
In this study, we investigated the associations of low-moderate arsenic exposure 
and arsenic metabolism with diabetes in the Strong Heart Study (SHS). The SHS is a 
population-based prospective cohort study of cardiometabolic diseases among 3 
American Indian communities in rural Arizona, Oklahoma, and North and South Dakota 
(“the Dakotas”).28 In participants from Arizona and the Dakotas, drinking water was 
probably the major source of inorganic arsenic while in participants from Oklahoma, diet, 
including rice, flour and other grains, was probably the main source. Urine arsenic 
concentrations and measures of arsenic metabolism were stable in SHS participants 
during the time of follow-up, supporting the use of urine arsenic as a suitable surrogate 
for chronic arsenic exposure and metabolism.29 In the SHS, we recently found that higher 
inorganic arsenic exposure was associated with higher diabetes prevalence,6 supporting 
the need to further investigate the prospective associations between arsenic exposure and 




In 1989-1991, the Strong Heart Study examined 4,549 American Indian men and 
women aged 45 to 74 years at baseline enrollment from 13 tribes and communities.30 All 
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community members were invited to participate in Arizona and Oklahoma, whereas a 
cluster sampling procedure was used in the Dakotas.31, 32 The overall participation rate 
was 62%. Compared with nonparticipants, participants were similar in age, body mass 
index, and prevalence of self-reported diabetes but were more likely to be female and to 
have self-reported hypertension.32 Participants were invited to subsequent clinical visits 
between 1993 and 1995, and between 1998 and 1999.31, 32 The SHS population is very 
stable, with low migration rates due to strong cultural and social links in the 
community.33 The Indian Health Service, institutional review boards, and participating 
communities approved the study protocol. All participants provided informed consent. 
The prevalence of diabetes in the Strong Heart Study in 1989-1991 was 50%. For 
this study, we used data from participants free of diabetes and with sufficient urine 
available for arsenic measurements at the baseline visit (N=1,986) (Supplementary figure 
1). We further excluded 117 participants lost during follow up or missing both fasting 
glucose and 2-hour plasma glucose data during follow-up, 105 participants with inorganic 
or methylated arsenic species below the limit of detection as it is difficult to estimate 
arsenic methylation in these participants, and 70 participants missing other variables of 
interest leaving 1,694 participants for this analysis.  
Data Collection 
Baseline clinical information consisted of a personal interview, physical 
examination, fasting blood sample, and spot urine sample.31 Sociodemographic (age, sex, 
and education) and lifestyle (smoking and alcohol status) information was collected by 
trained and certified interviewers using standardized questionnaires.31 Physical 
examination measurements (height, weight, waist and hip circumferences, and systolic 
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and diastolic pressures) and bio-specimen collection (blood and urine) were conducted by 
centrally trained nurses and medical assistants following a standardized protocol.31  
Detailed procedures of clinical and laboratory examinations have been described.31  
Estimated glomerular filtration rate at baseline was calculated using the Chronic Kidney 
Disease Epidemiology Collaboration (CKD-EPI) formula.34 Participants were asked to 
fast for 12 hours before blood samples were collected in the morning, at baseline and in 
the two subsequent visits. Spot urine samples were also collected in the morning and 
were frozen with 1 to 2 hours of collection. The biospecimens were stored at -70°C or 
lower before analyses.31  
Diabetes measurements 
Fasting plasma glucose level was determined by a hexokinase method at MedStar 
Health Research Institute, Washington, DC. A 2-hour, 75g oral glucose tolerance test was 
performed on all participants except those who were under insulin therapy, remained with 
poor glycemic control on oral medication, or had a fasting glucose level greater than 225 
mg/dL determined by Accu-Chek II (Baxter Healthcare, Grand Prairie, Texas).31  
Glycated hemoglobin was measured at the laboratory of the National Institute of Diabetes 
and Digestive and Kidney Diseases Epidemiology and Clinical Research Branch, 
Phoenix, Arizona, by a high-performance liquid-chromatographic (HPLC) method. 
Diabetes was defined as a fasting plasma glucose ≥126 mg/dL, plasma glucose ≥200 
mg/dL 2–h after ingestion of 75 g oral glucose load, self-reported diabetes history, and 




To assess long-term arsenic exposure, we measured urine arsenic species after 
confirmation that concentrations were stable over a 10-year period.29 Detailed analytic 
methods and associated quality control procedures for arsenic analysis have been 
published.35 Arsenic species concentrations were determined by high-performance liquid 
chromatography (HPLC) coupled to inductively coupled plasma mass spectrometry (ICP-
MS) that served as the arsenic selective detector (Agilent 1100 HPLC and Agilent 7700x 
ICP-MS, Agilent Technologies, Santa Clara, California). Arsenic speciation can 
discriminate species directly related to iAs exposure (arsenite, arsenate, 
monomethylarsonate [MMA], and dimethylarsinate [DMA]) from those related to 
organic arsenicals in seafood (arsenobetaine as an overall marker of seafood arsenicals), 
which are generally considered nontoxic.36 Urine concentrations of arsenobetaine and 
other arsenic cations were very low (median, 0.71; interquartile range, 0.41 to 1.69 μg/g 
creatinine), confirming that seafood intake was low in this sample, and indicating that 
DMA mainly came from inorganic arsenic exposure.37 The limit of detection for total 
arsenic and for iAs (arsenite plus arsenate), MMA, DMA, and arsenobetaine plus other 
arsenic cations was 0.1 μg/L. Because a major goal of the study was to evaluate the role 
of arsenic metabolism in diabetes development, we excluded participants with iAs 
(5.2%), MMA (0.8%) and DMA (0.03%) below the limit of detection. An in-house 
reference urine and the Japanese National Institute for Environmental Studies No. 18 
Human Urine were analyzed together with the samples. Interassay coefficients of 
variation for iAs, MMA, DMA and arsenobetaine for the in-house reference urine were 




We used the sum of urine inorganic (iAS; arsenite and arsenate) and methylated 
arsenic species (MMA and DMA) as the biomarker of inorganic arsenic exposure from 
multiple sources. We used the proportions of urine iAs, MMA and DMA over the sum of 
inorganic and methylated species, expressed as iAs%, MMA%, and DMA%, to evaluate 
arsenic metabolism.  We graphically described the distribution of arsenic metabolism in 
people with and without diabetes using a triplot, a diagram with 3 axis that is well-suited 
to represent arsenic metabolism (Figure 1). 
The prospective associations between arsenic exposure and arsenic metabolism 
with incident diabetes were evaluated by Cox proportional hazards models. Arsenic 
exposure was evaluated based on the urinary concentration of the sum of inorganic and 
methylated arsenic species. We also evaluated the urinary concentration of iAs, MMA 
and DMA in separate models. Arsenic metabolism was evaluated as iAs%, MMA% and 
DMA%. Similar to previous studies,20, 38, 39 we first entered each arsenic metabolism 
biomarker alone in the regression model together with the sum of inorganic and 
methylated arsenic species to adjust for arsenic exposure. Entering each biomarker alone 
is difficult to interpret, as the increase in iAs, for instance, could be related to a decrease 
in either MMA or DMA. To address this problem, we used a “leave-one-out” approach. 
In this method, two biomarkers are entered at a time, e.g. iAs% and MMA%, leaving out 
the third one, DMA%, while holding constant urine arsenic concentrations. In the 
example, the regression coefficients for iAs% and MMA% estimate the hazard ratio 
associated with an increase in iAs% by decreasing DMA%, and with an increase in 
MMA% by decreasing DMA%, respectively. This method is used in the nutrition 
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literature to estimate the specific contribution of different macronutrients beyond their 
contribution to total energy intake as well as in the hematology literature to estimate the 
specific contribution of different blood cell types beyond total cell count.40, 41  
All arsenic variables were modeled per interquartile range increment (in the log 
scale for urine arsenic species concentrations and in the original scale for % species) and 
using restricted cubic splines. We also modeled them using quartiles with similar findings 
(data not shown). The time scale for survival analysis was age. To handle left-truncation 
induced at time of enrollment and appropriately aligning risk sets on the age scale, the 
late entry method was conducted using age at baseline as the individual entry time. 
Models were adjusted progressively. Initially, we adjusted for sex and education (no high 
school, some high school, and high school or more). We then adjusted further for 
smoking and alcohol drinking status. Finally, we further adjusted for body mass index 
and waist–hip ratio. All models were adjusted for urine creatinine to account for urine 
dilution. In an alternative analysis we adjusted for specific gravity instead of urine 
creatinine. Both models yielded similar results (models for specific gravity are not 
shown). We confirmed that the proportional hazards assumption was fulfilled based on 
Schoenfeld residuals.  
We conducted additional sensitivity analyses to evaluate the robustness of our 
primary findings. First, we evaluated the prospective associations of arsenic exposure and 
arsenic metabolism with incident diabetes by fitting generalized gamma distributions to 
survival times. Model selection was based on the Akaike Information Criterion (AIC) and 
estimates for the shape parameter indicated that log-normal distributions were 
appropriate. This approach yielded consistent findings as the Cox proportional hazards 
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model (data not shown). Second, because mortality rate was high in the SHS 
population,42 we conducted competing risk analysis of death based on Fine and Gray’s 
method, which yielded similar statistical inference.43 We also used generalized gamma 
modeling to describe the competing relationship between mortality and incident diabetes 
according to arsenic exposure status (supplementary figure 2).44 Third, we repeated the 
analysis for arsenic exposure including participants who had iAs, MMA or DMA below 
the limit of detection (LOD) by replacing levels below the LOD by the LOD divided by 
the square root of 2, also with similar findings (not shown).  
 All statistical analyses were performed in Stata/IC, version 12 (StataCorp, College 
Station, Texas) and R, version 3.0.2 (R Foundation for Statistical Computing, Vienna, 
Austria [www.r-project.org]).  
 
Results 
The median urine concentration of inorganic plus methylated arsenic species was 
10.2 μg/L  (interquartile range, 6.1 to 17.7 μg/L). Urine arsenic concentrations were 
higher in participants from Arizona (median 14.3 μg/L), followed by the Dakotas (11.9 
μg/L) and Oklahoma (median 7.0 μg/L ). The median (interquartile range) for iAs%, 
MMA% and DMA% was 8.3 (5.7 to 11.3)%, 15.2 (11.7 to 18.8)% and 76.4 (70.3 to 
81.4)%, respectively. Men, participants from the Dakotas, current smokers and 
participants with lower body mass index had higher MMA%, and correspondingly lower 
DMA% (Figure 2). 
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Over 11,263.2 person-years of follow-up, 396 participants developed diabetes. 
Diabetes incidence was 35.2 per 1000 person-years. Participants with incident diabetes 
were more likely to be female, from Arizona, and obese at baseline (Table 1). Younger 
age was borderline associated with incident diabetes (p-value 0.05). Urine concentrations 
of inorganic plus methylated arsenic were similar in participants with and without 
incident diabetes. Participants with incident diabetes had lower MMA% and higher 
DMA% compared to those without incident diabetes (Table 1, Figure 1). Arsenic 
exposure, assessed as the summed concentrations in urine of inorganic and methylated 
arsenic species or as each of the individual arsenic species, was not associated with 
incident diabetes in any of the multivariable adjusted models (Table 2 and Supplement 
Figure 3).  
For arsenic metabolism, the multi-adjusted hazard ratio (95% CI) of diabetes 
incidence per IQR in arsenic metabolism biomarkers entered one-by-one in the model 
(conventional approach) was 1.00 (0.87-1.14) for iAs%, 0.79 (0.68-0.92) for MMA% and 
1.17 (1.00-1.36) for DMA% (Table 3, model 4). Using the leave-one-out approach, we 
confirmed that increasing MMA% was associated with decreased diabetes incidence. The 
hazard ratios (95% CI) of diabetes incidence for an IQR change in MMA% were 0.69 
(0.52, 0.90) and 0.76 (0.65, 0.89) when iAs% and DMA% were, respectively, left-out of 
the model (Table 3, model 4). Consistently, increasing MMA% was related to decreased 
diabetes incidence in flexible dose-response analyses when either iAs% or DMA% were 
left-out of the model (Figure 3). DMA% was associated with increased diabetes 
incidence only when substituted for MMA% and iAs% was associated with increased 
diabetes incidence only when substituted for MMA% (Table 3, Figure 3).  
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The association between MMA% and diabetes incidence was similar by age, sex, study 
site, obesity, and the sum of inorganic and methylated arsenic concentrations 
(Supplementary table 1).  
 
Discussion 
Arsenic metabolism, but not inorganic arsenic exposure, was prospectively 
associated with diabetes incidence in American Indians from Arizona, Oklahoma and 
North/South Dakota. Higher iAs% and DMA% in urine, because of lower MMA%, was 
associated with higher diabetes incidence.  Consistently, higher MMA% was associated 
with lower risk of diabetes. The associations persisted after adjustment for 
sociodemographic factors, smoking, alcohol, kidney function, and measures of adiposity. 
These novel findings support that arsenic metabolism patterns, in particular lower 
MMA%, may be a predisposing factor for diabetes. Arsenic exposure, measured by the 
concentration of inorganic plus methylated arsenic species in urine, however, was not 
associated with diabetes incidence in our study population. The study was conducted in a 
population with a high burden of obesity and diabetes45 and characterized by low-to-
moderate arsenic exposure levels.  
Non-genetic determinants of arsenic metabolism include sex (women have higher 
DMA% than men), smoking (never smokers generally have higher DMA% than current 
smokers), nutritional status (dietary folate and vitamin deficiencies are associated with 
lower DMA%), and BMI (obese participants have higher DMA%).9 In women, MMA% 
decreases and DMA% increases during pregnancy.46, 47 While the risk of gestational 
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diabetes is also increased, a connection with changes in arsenic metabolic patterns during 
pregnancy is unknown.48, 49 Interestingly, in our study the arsenic metabolic pattern 
associated with increased diabetes risk paralleled that observed during pregnancy, i.e., 
lower MMA% and higher DMA%. Genetic determinants, especially variants in arsenic 
(III) methyltransferase (AS3MT), have also been related with arsenic methylation patterns 
in urine.50, 51 Additional research is needed to evaluate whether genetic variants play a 
role in the connection between arsenic metabolism profile and diabetes.  
Little is known about arsenic metabolism and diabetes as compared to its role in 
cancer and cardiovascular disease.14, 52-55 In those studies, conducted mostly in Taiwan 
and Bangladesh, higher MMA% was associated with the development of lung54, 
bladder52 and skin53 cancers and with cardiovascular disease including atherosclerosis 
and peripheral vascular disease.14, 55 In one small case-control study from Bangladesh, 
higher DMA% was associated with increased prevalence of diabetes, although the 
association was not statistically significant.20 High BMI has also been significantly 
associated with low MMA% and high DMA% in urine in adults from Mexico and the 
Strong Heart Study.21, 22 In our study, adjusting for baseline BMI and waist-hip ratio 
slightly attenuated the association between arsenic metabolism and incident diabetes, 
although the association remained. How this specific pattern (low MMA% with either 
high iAs% or DMA%) may affect individual susceptibility to endocrine and metabolic 
diseases remains unclear.   
Substantial experimental research supports the role of arsenic exposure in diabetes 
development.2, 3 Experimental studies, in general, have not focused on differences by 
arsenic metabolism. High MMA% may be considered as a marker of insufficient 
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methylation capacity to DMA. Recent experimental studies have shown that methylation 
could be a bio-activation process, with DMA(III) being a potent and highly toxic 
dimethylated arsenic species.56, 57 DMA(III) was found to impair insulin signaling and 
glucose homeostasis.17, 58 In a cross-sectional study from Mexico, the concentrations of 
DMA(III) in urine were associated with diabetes.5 In our study, similar to other large 
epidemiologic studies, we measured total MMA and DMA, as MMA(III) and  DMA(III) 
are unstable in urine and quickly revert to their pentavalent forms.59  
The association of arsenic metabolism with diabetes could also be related to one 
carbon metabolism, as S-adenosylmethionine (SAM) is the methyl donor for arsenic 
metabolism.24, 60 Recent experimental evidence has shown that SAM plays an important 
role in lipogenesis and in the development of diabetes.26, 61, 62 An in vitro study in 
Caenorhabditis elegans, an experimental model for human diseases and metabolic 
pathways,63, 64 found that the synthesis of SAM regulated the expression of genes 
required for adequate lipid metabolism.61 In HepG2 human hepatocytes, the optimal 
balance between SAM and S-adenosylhomocystine (SAH) was critical to maintain 
appropriate expression of gluconeogenic enzymes.62 In addition, in a cross-sectional 
study of 50-75 year old adults from the Netherlands (N=648), plasma SAM was 
positively associated with fat mass and truncal adiposity, although reverse causation 
could not be excluded.65 We cannot discount the possibility that arsenic metabolism acts 
as a marker of one carbon metabolism. In any case, our findings indicate that more 
research is warranted to understand the impact of arsenic methylation and other 
methylation processes related to one-carbon metabolism on the development of diabetes.  
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In our study, we found no association between arsenic exposure and incident 
diabetes, although cross-sectionally we had found an association.6 Inorganic arsenic and 
its methylated metabolites may induce diabetes by impairing insulin production by 
pancreatic ß cells or inhibiting basal or insulin-stimulated glucose uptake by peripheral 
tissues.10, 66 Relevant mechanisms by which arsenic could affect ß-cell function and 
insulin sensitivity include oxidative stress, glucose uptake and transport, 
gluconeogenesis, adipocyte differentiation, calcium signaling, and epigenetic effects.2, 10 
A number of recent studies have reported a prospective association between arsenic 
exposure and diabetes development 3, 7, 8 It is possible that arsenic exposure is not a risk 
factor for diabetes in our population. At the same time, the presence of an association 
between arsenic exposure and diabetes cross-sectionally but not prospectively could be 
related to competing risk of premature death and differential survival bias that may mask 
the true association in our population. Because arsenic was strongly associated with 
diabetes at baseline and the prevalence of diabetes at baseline was 50%,6 another possible 
explanation for the lack of association is that the pool of susceptible participants is too 
small for the association to be seen prospectively. In support of this possibility, age was 
not positively associated with diabetes incidence either (Table 1). BMI, however, 
remained a strong risk factor.  
Strengths of our study include standardized protocol to collect data over the 
follow-up, high-quality laboratory methods for measuring concentrations of urine arsenic 
species at baseline and careful modeling of the dynamic of arsenic metabolism including 
the leave-one-out approach. This study had several limitations. First, the urine arsenic 
concentrations and metabolism were measured in a single sample at baseline to represent 
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internal doses and individual metabolism profiles. However, we have confirmed that 
arsenic levels in urine and arsenic metabolism were constant over 10-years in this 
population.29 Second, adjustment for adiposity could induce over-adjustment as obesity 
may be in the causal pathway between arsenic metabolism and diabetes. Finally, our 
population was between 40 and 74 years of age and the burden of diabetes at baseline 
was already 50%. It is thus possible that participants susceptible of developing diabetes at 
baseline were different from the source population. Studies in younger populations with a 
lower prevalence of diabetes at baseline are needed.  
In conclusion, arsenic metabolism, in particular low MMA%, was associated with 
increased incidence of diabetes and could reflect individual susceptibility for diabetes 
development. Arsenic metabolism is related to one-carbon metabolism, and could be 
functioning as a surrogate measure of one-carbon metabolism. Research is needed to 
assess the relationship between arsenic metabolism and diabetes in different populations, 
evaluate the diabetogenic role of arsenic metabolism in experimental settings, and clarify 
whether the development of diabetes is related to arsenic metabolism specifically or to 
















  N (%) Median(IQR) N %  Median(IQR)  
Age, year  54.6 (48.8‐61.8)   53.3 (48.5‐60.3) 0.05 
Male  610 (47.0) 153 (38.6)    <0.01 
Location       
  Arizona  255 (19.7) 114 (28.8)    <0.01 
  Oklahoma  504 (38.8) 109 (27.5)     
  North and South Dakota  539 (41.5) 173 (43.7)     
Education (yrs)      0.06 
  No high school  230 (17.7) 91 (23.0)     
  Some high school  305 (23.5) 89 (22.5)     
  High school or more  763 (58.8) 216 (54.6)     
Smoking (%)      0.05 
  Never  353 (27.2) 126 (31.8)     
  Former  398 (30.7) 129 (32.6)     
  Current  547 (42.1) 141 (35.6)     
Alcohol (%)      0.19 
  Never  158 (12.2) 61 (15.4)     
  Former  499 (38.4) 154 (38.9)     
  Current  641 (49.4) 181 (45.7)     
Body mass index  28.0 (25.0‐31.9)   30.9 (28.1‐35.3) <0.01 
Waist‐hip ratio  0.94 (0.89‐0.98)   0.96 (0.92‐0.99) <0.01 
Waist circumference (cm)  98 (91‐107)   106 (98‐116) <0.01 
% Body fat  33.3 (27.1‐40.8)   38.5 (31.1‐44.3) <0.01 
Urine creatinine, g/L  1.3 (0.8‐1.8)   1.2 (0.9‐1.7) 0.80 
eGFR , ml/min/1.73m2  81.3 (71.6‐92.7)   81.1 (70.8‐93.7) 0.48 
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Fasting glucose, mg/dL  100 (93‐107)   106 (98‐113) <0.01 




8.7 (5.3‐13.8)   9.1 (5.9‐14.0) 0.32 
iAs, g/g  0.7 (0.4‐1.4)   0.7 (0.4‐1.3) 0.87 
MMA, g/g  1.3 (0.8‐2.2)   1.2 (0.8‐2.1) 0.58 
DMA, g/g  6.4 (4.0‐10.3)   7.0 (4.4‐11.2) 0.16 
Arsenic metabolism     
iAs%  8.4 (5.7‐11.6)   8.1 (5.7‐10.7) 0.09 
MMA%  15.5 (12.0‐19.1)   14.0 (11.2‐17.1) <0.01 
























Arsenic (interquartile range)  Model 1  Model 2  Model 3  Model 4 
iAs (0.4‐1.4 μg/g)  0.87 (0.74‐1.01) 0.86 (0.74‐1.01)  0.88 (0.75‐1.04) 0.95 (0.81‐1.12)
MMA ( 0.8‐2.2 μg/g)  0.78 (0.66‐0.91) 0.76 (0.64‐0.89)  0.77 (0.65‐0.90) 0.85 (0.72‐1.00)
DMA ( 4.0‐10.5 μg/g)  1.00 (0.86‐1.17) 0.95 (0.81‐1.11)  0.96 (0.82‐1.13) 0.98 (0.83‐1.15)





























Arsenic metabolism (interquartile range)  Model 1  Model 2  Model 3  Model 4 
Conventional approach         
iAs% (5.7‐11.3)  0.88 (0.78‐1.00) 0.91 (0.80‐1.04)  0.92 (0.81‐1.05) 1.00 (0.87‐1.14)
MMA% (11.7‐18.8)  0.69 (0.60‐0.80) 0.70 (0.60‐0.81)  0.70 (0.61‐0.82) 0.79 (0.68‐0.92)
DMA% (70.3‐81.4)  1.35 (1.17‐1.55) 1.33 (1.15‐1.53)  1.31(1.13‐1.52)  1.17 (1.00‐1.36)
Leave‐one‐out approach          
↑iAs% corresponds to:         
  ↓MMA% (11.7‐18.8)  1.37 (1.11‐1.69) 1.39 (1.13‐1.70)  1.40 (1.14‐1.72) 1.35 (1.09‐1.67)
  ↓DMA% (70.3‐81.4)  1.01 (0.89‐1.15) 1.03 (0.91‐1.17)  1.04 (0.92‐1.19) 1.09 (0.95‐1.24)
↑MMA% corresponds to:         
  ↓iAs% (5.7‐11.3)  0.67 (0.52‐0.88) 0.66 (0.51‐0.86)  0.66 (0.50‐0.85) 0.69 (0.52‐0.90)
  ↓DMA% (70.3‐81.4)  0.69 (0.59‐0.80) 0.69 (0.59‐0.81)  0.69 (0.59‐0.81) 0.76 (0.65‐0.89)
↑DMA% corresponds to:         
  ↓iAs% (5.7‐11.3)  0.97 (0.76‐1.25) 0.94 (0.73‐1.21)  0.92 (0.71‐1.19) 0.85 (0.65‐1.11)

























































Age (years)           
  < 55  902  0.88 (0.72‐1.08)  0.47  0.80 (0.65‐1.00)  0.31 
  ≥ 55   792  1.00 (0.77‐1.28)    0.67 (0.52‐0.87) 
Sex           
  Men    763  1.12 (0.87‐1.43)  0.36  0.84 (0.66‐1.07)  0.72 
  Women  931  0.86 (0.70‐1.06)    0.69 (0.55‐0.87) 
Study site           
  Arizona  369  0.96 (0.68‐1.34)  0.91  0.68 (0.48‐0.96)  0.52 
  Oklahoma   613  0.94 (0.68‐1.29)    0.69 (0.50‐0.94)   
  North/South Dekota  712  0.95 (0.76‐1.18)    0.85 (0.67‐1.07)   
Smoking           
  Never  479  0.77 (0.57‐1.03)  0.31  0.81 (0.60‐1.11)  0.72 
  Former  527  1.14 (0.85‐1.53)    0.68 (0.50‐0.91) 
  Current  688  1.03 (0.80‐1.33)    0.83 (0.63‐1.09) 
Obesity           
  Non‐obese (BMI< 30 kg/m2)  993  0.84 (0.65‐1.07)  0.39  0.73 (0.58‐0.93)  0.62 
  Obese (BMI≥ 30)  701  1.02 (0.82‐1.26)    0.76 (0.61‐0.95) 
Waist‐hip ratio           
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  Non‐abdominal obesity*  625  1.01 (0.70‐1.45)  0.75  0.64 (0.45‐0.91)  0.23 
  Abdominal obesity  1069  0.94 (0.79‐1.13)    0.79 (0.66‐0.96)   
iAs+MMA+DMA           
 5.5 g/g creatinine   426  ‐‐    0.89 (0.63‐1.28)  0.80 
> 5.5 &  8.8 g/g creatinine  421  ‐‐    0.63 (0.45‐0.89) 
>8.8 &  13.9 g/g creatinine  424  ‐‐    0.73 (0.52‐1.02) 
> 13.9 g/g creatinine  423  ‐‐    0.74 (0.53‐1.03) 
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where F and G were the survival functions corresponding to the f and g densities, respectively.  	 1  is the cumulative 






Full Saturated Model    Incident diabetes  Death   
  %  β1  σ1  κ1  β2  σ2  κ 2  AIC 
Reference group (Quartile 1)  0.727 2.60  0.95  0.0001  2.56  0.87  1  5506.978
Arsenic (Quartile 2)  0.645 2.36  0.92  0.0001  2.65  0.60  1   
Arsenic (Quartile 3)  0.809 2.55  1.00  0.0001  1.90  0.64  1   
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Context:  The role of arsenic metabolism in kidney disease remains unclear and relevant 
evidence is scarce.  
Objective:  To assess the prospective association between arsenic metabolism and 
kidney disease in American Indian population exposed to low-moderate levels of arsenic. 
Design, Setting, and Participants: Prospective cohort study in 3,143 American Indian 
participants aged 45 to 75 years living in Arizona, Oklahoma, and North and South 
Dakota. The sum of urine inorganic arsenic (arsenite and arsenate), monomethylated 
(MMA), and dimethylated (DMA) arsenic compounds at baseline was used as the 
biomarker of inorganic arsenic exposure from multiple sources. The proportions of urine 
inorganic arsenic (arsenite and arsenate, iAs), MMA and DMA over the sum of inorganic 
and methylated species, expressed as iAs%, MMA%, and DMA%, was used to evaluate 
arsenic metabolism. 
Main outcome measures:  Kidney disease was determined by estimated glomerular 
filtration rate (eGFR), eGFR drop greater than 25%, macroalbuminuria, and renal 
replacement therapy requirements.  
Results: The median (interquartile range) for inorganic arsenic%, MMA% and DMA% 
was 8.3 (5.8 to 11.2), 13.9 (10.8 to 17.4) and 77.5 (71.7 to 82.5), respectively. In multi-
adjusted Cox proportional hazards model, the hazard ratio of incident kidney disease 
defined by reduced eGFR for an interquartile range increase in iAs% was 0.62 (95% CI 
0.49-0.78) and 0.73 (0.63-0.85) when it substituted MMA% and DMA%, respectively. 
The adjusted hazard ratio was 1.23 (1.06-1.43) for an interquartile increase in MMA% 
with a corresponding decrease in DMA%. The results were robust to different kidney 
115 
 
disease definitions. The effects of replacing iAs% by MMA% or DMA% on the risk of 
developing kidney disease displayed a linear dose-response relationship and were 
enhanced among obese participants defined by body mass index higher than 30 kg/m2. 
Conclusion:  Arsenic metabolism is independently and prospectively associated with the 
development of chronic kidney disease. Integrating the information of arsenic 
methylation capacity is therefore important for arsenic risk assessment. More research is 
needed to verify our results and further explore the pathogenesis of arsenic-related kidney 
injury from the viewpoints of systemic metabolism, epigenomics, and the interaction with 

















Arsenic (As) is a naturally-occurring element found in rock, soil and water and 
extensively used in anthropogenic activities leading to its ubiquitous presence in the 
environment. In addition to the well-recognized adverse effects of inorganic arsenic 
including carcinogenicity, cardiovascular toxicity, and diabetogenic potential, recent 
research has found the association between inorganic arsenic and chronic kidney 
disease (CKD).1, 2 Although the molecular mechanisms underlying the pleiotropic 
effects of long-term arsenic exposure remains poorly understood, arsenic metabolism 
is considered to play a critical role as the elimination process of arsenic involving an 
interplay between arsenic methylation and one-carbon metabolism, a complex 
metabolic network linking to diverse diseases such as cancer and cardiovascular 
diseases.3 In humans, absorbed inorganic arsenic (arsenate and arsenite) is primarily 
methylated in the liver to form monomethylated (MMA) and dimethylated (DMA) 
arsenic compounds, which are excreted into the urine with unchanged inorganic 
arsenic. The proportion of arsenic species in urine is 10-30% for inorganic arsenic, 
10-20% for MMA, and 60-80% for DMA with substantial inter-individual variation.4, 
5 Increasing evidence has supported the different arsenic methylation patterns may 
associate with certain diseases and physiologic status.  Higher MMA% in urine has 
been related to increased risk of cancer and cardiovascular disease while higher 
DMA% has also been related to diabetes and obesity.1, 6-8 However, little is known 
about the association between arsenic metabolism and CKD.  
CKD is a key determinant of poor health outcomes and imposes significant 
financial costs on health care system.9, 10 The prevalence of CKD defined by reduced 
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estimated filtration rate (eGFR< 60 ml/min/1.73m2) or albuminuria (urine albumin-
to-creatinine ratio ≥ 30 mg/g) is 10% to 15% of adults in developed countries such as 
United States11, Europe12, and Asia13 and may be even higher in developing countries 
including China14 and the Central America.15 The US Surgeon General’s latest report, 
Healthy People 2020, has recognized CKD as an important public health issue and 
recommended systemic preventive strategies including early detection and effective 
treatment of CKD.16 The first three leading causes of CKD in the United States 
include diabetes, hypertension, and glomerulonephritis.17 However, the epidemiology 
of CKD is not consistent across countries. For instance, less than 20% of incident 
patients with end stage renal disease (ESRD) in Norway, Netherlands, and Russia are 
related to diabetes in contrast to about 45% and 60% in United States and Singapore, 
respectively.17 The disproportionally high prevalence of diabetes among ESRD 
patients in certain countries supports the hypothesis that individual susceptibility to 
CKD may be intertwined with genetic and environmental factors such as pollution, 
nutritional or lifestyle transition, population growth and urbanization, or alteration of 
population age structure.18   
This study examined the association between arsenic exposure and arsenic 
metabolism with incident CKD in the Strong Heart Study (SHS). Understanding the 
role of arsenic metabolism in the development of CKD is important to approach risk 
assessment from a differential-susceptibility perspective. The connection between 
arsenic metabolism and one-carbon metabolism may offer an opportunity for 
prevention strategies to ameliorate arsenic toxicity and modify individual 





Study population  
 The Strong Heart Study (SHS) is a population-based study examining 
cardiovascular diseases and diabetes in men and women aged 45 to 74 years between 
1989 and 1991 in 13 American Indian tribes and communities from Arizona, Oklahoma, 
and North and South Dakota.19 All eligible community members were invited to 
participate in Arizona and Oklahoma, whereas a cluster sampling technique was applied 
in the Dakotas.19 The overall participation rate was 62%, and a total of 4,549 participants 
were enrolled. Participants were then invited to subsequent clinical visits between 1993 
and 1995 and between 1998 and 1999. The SHS was a stable population with low 
migration rate over the follow-up period as most adults live in the community of their 
birth and have strong cultural and social links in the community.20, 21 Compared to 
nonparticipants, participants were similar in age, body mass index, and self-reported 
diabetes but were more likely to be female and to have self-reported hypertension.22 The 
Indian Health Service, institutional review boards, and participating tribes approved the 
study protocol. All participants provided informed consent.  
We used data from 3,973 participants with sufficient urine available for arsenic 
quantification at the baseline visit. We further excluded 228 participants with some 
arsenic species data (inorganic arsenic, MMA or DMA) below the limit of detection, 5 
missing education, 10 missing smoking or alcohol drinking status, 42 missing body mass 
index or waist-hip ratio, 67 missing baseline estimated glomerular filtration rate (eGFR) 
or urine albumin-creatinine ratio (UACR), and 151 missing both eGFR measures during 
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follow-up,  leaving 3,470 eligible participants. . We then excluded 327 participants with 
reduced eGFR < 60 ml/min/1.73m2 or end stage renal disease (ESRD) on renal 
replacement therapy at baseline, leaving 3,143 participants in this analysis. Included 
participants were similar to those who were excluded because of missing data (data not 
shown).  
Data collection 
Baseline clinical information included a personal interview, physical examination, 
fasting blood test, and spot urine sample collection.19 Socidemographic (age, sex, and 
education) and lifestyle (smoking and alcohol status) information was collected by 
trained and certified interviewers using standardized questionnaires.19 Physical 
examination measurements (height, weight, waist and hip circumferences, and systolic 
and diastolic pressures) and bio-specimen collection (blood and urine) were conducted by 
centrally trained nurses and medical assistants following a standardized protocol.19  
Detailed procedures of clinical and laboratory examinations have been published.19  
Participants were asked to fast for 12 hours before blood samples were taken in the 
morning, at baseline and in the two subsequent visits. Spot urine samples were also 
collected in the morning and were frozen with 1 to 2 hours of collection. The 
biospecimens were stored at -70°C or lower before analyses.19 Urine creatinine was 
measured by an automated alkaline picrate method. Specific gravity was measured with a 
Leica TS 400 total solid refractometer (Leica Microsystems, Buffalo, USA).   
Kidney function measurements 
 Serum creatinine measures were conducted by a single core laboratory and 
determined by automated alkaline picrate methodology.23 The estimated glomerular 
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filtration rate (eGFR) was estimated by using the Modification of Diet in Renal Disease 
Study equation:24  
 eGFR (mL/min/1.73m2)= 186.3  (Serum creatinine) -1.154  (Age) -0.203  
        0.742 (if female)  
        1.210 (if African-American) [not applicable in our 
study] 
 
 Urine albumin and creatinine were measured at the Laboratory of the National 
Institute of Diabetes and Digestive and Kidney Diseases, Epidemiology and Clinical 
Research Branch, Phoenix, AZ, by an automated nephelometric immunochemical 
procedure and an automated alkaline picrate methodology, respectively.19 Urine albumin-
to-creatinine ratio (UACR) was used to estimate 24-hour urine albumin excretion. 
Macroalbuminuria was defined as a UACR > 300 mg/g creatinine.25  
CKD definitions 
To date, an operative definition of incident CKD has not yet been explicitly 
defined.26 In this study, incident CKD was defined by increasingly more specific criteria 
to evaluate the sensitivity of results to different outcome definitions.  First, incident cases 
with a reduced eGFR were defined as an eGFR less than 60 ml/min/1.73m2 at visit 2 or 
visit 3. Second, incident cases with a reduced and a declining eGFR were defined as an 
eGFR less than 60 ml/min/1.73m2 and a drop in eGFR of at least 25% at visit 2 or visit 3 
(called thereafter “impaired eGFR”). Third, incident cases with both impaired renal 
function and macroalbuminuria were defined as an eGFR less than 60 ml/min/1.73m2 and 
a drop in eGFR of at least 25%, and urine albumin-creatinine ratio ≥ 300 mg/g creatinine. 
121 
 
Fourth, incident cases of renal failure were defined as a doubling in serum creatinine 
levels or progression to end-stage renal disease (ESRD).27 ESRD was defined as a 
requirement for maintenance renal replacement therapy including both dialysis and 
transplantation.28   
Urine arsenic measurements 
The urine concentrations of arsenic species in Strong Heart Study population was 
stable over a 10-year follow up, reflecting stability in arsenic exposure and the 
appropriate of one single arsenic measure to represent long-term arsenic exposure.29 
Detailed analytic methods and associated quality control procedures for arsenic analysis 
have been described.30 Arsenic species concentrations were determined by high-
performance liquid chromatography (HPLC) coupled to inductively coupled plasma mass 
spectrometry (ICP-MS) that served as the arsenic selective detector (Agilent 1100 HPLC 
and Agilent 7700x ICP-MS, Agilent Technologies, Santa Clara, California). Arsenic 
speciation could discriminate species directly related to inorganic arsenic exposure 
(arsenite, arsenate, monomethylarsonate [MMA], and dimethylarsinate [DMA]) from 
those related to organic arsenicals in seafood (arsenobetaine as an overall marker of 
seafood arsenicals), which are generally considered nontoxic.31 The limit of detection 
(LOD) for total arsenic and for inorganic arsenic (arsenite plus arsenate), MMA, DMA, 
and arsenobetaine plus other arsenic cations was 0.1 μg/L. The percentages of 
participants with concentrations below the limit of detection were 0.03% for total arsenic, 
5.2% for inorganic arsenic, 0.8% for MMA, 0.03% for DMA, and 2.1% for arsenobetaine 
plus other arsenic cations. For participants with arsenic species below the LOD, levels 
were imputed as the corresponding LOD divided by the square root of 2. An in-house 
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reference urine and the Japanese National Institute for Environmental Studies No. 18 
Human Urine were analyzed together with the samples. Interassay coefficients of 
variation for total arsenic, inorganic arsenic, MMA, DMA and arsenobetaine for the in-
house reference urine were 4.4%, 6.0%, 6.5%, 5.9%, and 6.5%, respectively. 
Arsenic exposure and arsenic metabolism 
We used the sum of urine inorganic arsenic (arsenite and arsenate) and methylated 
arsenic species (MMA and DMA) as the biomarker of inorganic arsenic exposure from 
multiple sources.32-34 The urine arsenic concentrations were divided by urine creatinine 
levels to account for urine dilution-concentration and expressed as μg/g creatinine.  Urine 
concentrations of arsenobetaine and other arsenic cations were very low (median 0.68; 
interquartile range 0.42 to 1.50 μg/g creatinine), confirming that seafood intake was low 
in this sample, and indicating that DMA mainly came from inorganic arsenic exposure.35 
We used the proportions of urine inorganic arsenic (arsenite and arsenate, iAs), MMA 
and DMA over the sum of inorganic and methylated species, expressed as iAs%, 
MMA%, and DMA%, to evaluate arsenic metabolism. 
Statistical analyses 
 Urine concentrations of the sum of inorganic and methylated species were 
modeled as quartiles and as log-transformed concentrations to stabilize the variability for 
right-skewed variables to compare the 75th and 25th percentile (interquartile range, IQR). 
Arsenic metabolism (iAs%, MMA%, and DMA%) was modeled as per IQR increment.  
The primary analyses used Cox proportional hazards modeling to quantify the 
relative hazard of incident kidney disease associated with arsenic exposure and arsenic 
metabolism.36 The time scale for survival analysis was age, allowing to control over this 
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strong risk factor of chronic kidney disease. To handle left-truncation induced at time of 
enrollment and appropriately aligning risk sets on the age scale, the late entry method 
was conducted using age at baseline as the individual entry time. All proportional hazards 
models were adjusted for study site (using the stratified Cox procedure), education level 
(less than high school, some high school, high school or more), smoking status (never, 
former, current), alcohol drinking (never, former, current), body mass index,  waist-hip 
ratio, hypertension, diabetes, and fasting glucose. We conducted stratified analysis to 
explore the consistency of the association between arsenic metabolism and incident CKD 
across categories of these demographic and comorbid factors.   
 
Results 
Follow-up and kidney outcomes of participants 
From baseline through Dec 31, 1999, 474 (15.1 %) participants had reduced 
eGFR, 330 (10.5%) had reduced eGFR and a drop in eGFR of at least 25%, 206 (6.6%) 
had both impaired eGFR and macroalbuminuria, and 172 (5.5%) developed renal failure.  
Overall, median concentration of the sum of inorganic and methylated arsenic species in 
the urine was 11.2 μg/L (interquartile range, 6.7 to 19.6 μg/L). Urine arsenic 
concentrations were higher in participants from Arizona (median 15.1 μg/L ), followed 
by North and South Dakota (12.7 μg/L ) and Oklahoma (median 7.3 μg/L ). The median 
(interquartile range) for iAs%, MMA% and DMA% was 8.3 (5.8 to 11.2), 13.9 (10.8 to 
17.4) and 77.5 (71.7 to 82.5), respectively. Men, participants from North and South 
Dakota, current smokers and participants with lower body mass index had higher iAs% 
and MMA%, and correspondingly lower DMA%. 
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Arsenic exposure and chronic kidney disease 
 Compared with the overall population, baseline urine arsenic concentrations were 
higher among participants with incident kidney disease defined by reduced eGFR 
(definition 1), impaired eGFR (definition 2), impaired eGFR with macroalbuminuria 
(definition3), and renal failure (definition 4) (Table 1). The strength of the association 
between an interquartile range increase in baseline urine arsenic concentrations and 
kidney insufficiency increased from a fully adjusted hazard ratio of 1.07 (95% CI 0.90-
1.29) for participants with low eGFR (definition 1) to 1.49 (95% CI 1.10-2.01) for 
participants with renal failure (definition 4) (Table 2, Model 4).  
Arsenic metabolism and kidney disease 
 Compared with the overall population, participants with incident kidney disease 
had lower baseline iAs% and MMA% but had higher DMA% (Table 1). When modeling 
each arsenic metabolism biomarker one at a time in fully adjusted models, only the 
association with iAs% was statistically significant (Table 3). For each interquartile range 
increase in iAs%, the hazard ratio was 0.80 (95%CI 0.70 -0.92) for reduced eGFR, 0.81 
(CI 0.69-0.95) for impaired eGFR, 0.71 (0.58-0.87) for impaired eGFR and 
macroalbuminuria, and 0.73 (0.58-0.92) for renal failure (Table 3, model 4).  
When modeling arsenic metabolism by including two biomarkers in the model at 
the same time, the adjusted hazard ratio for reduced eGFR comparing an interquartile 
range increase in iAs% was 0.62 (95% CI 0.49-0.78) and 0.73 (0.63-0.85) when it 
substituted MMA% and DMA%, respectively.  The adjusted hazard ratio for an 
interquartile range increase in MMA% was 1.81 (95% CI 1.36-2.40) and 1.23 (1.06-1.43) 
when it substituted iAs% and DMA%, respectively. The adjusted hazard ratio for an 
125 
 
interquartile range increase in DMA% was 1.86 (1.37-2.52) and 0.71 (0.56-0.90) when it 
substituted iAs% and MMA%, respectively (Table 4, model 4). These association 
patterns were consistent across all incident CKD definitions (Table 4). In dose-response 
analyses, increasing MMA% and DMA% were related to increased risk of renal 
impairment when they substituted iAs% (Figure 1).  
The association between arsenic metabolism and incident CKD was similar by 
age, sex, study site, and the sum of inorganic and methylated arsenic concentrations. The 
association, however, was stronger in participants with obesity (Table 5).  
 
Discussion 
 Exposure to low to moderate arsenic levels of inorganic arsenic, as measured in 
urine, was prospectively associated with the development of kidney diseases. A specific 
pattern of arsenic metabolism was also significantly associated with increased risk of 
kidney diseases. The more arsenic is metabolized into methylated arsenic species in the 
body, the higher risk of developing kidney disease. The hypothetical rationale underlying 
this observation is that the unchanged form of arsenic may be less likely deposited in the 
renal tissue compared to MMA and DMA or that higher iAs% may reflect the relative 
inefficient arsenic methylation capacity in the renal tissue.  Differential toxicity toward 
renal injuries of each arsenic species is also important. However, the mechanism of 
arsenic-induced renal damage remains unknown. Whether the association is causal, from 
an epidemiological perspective, either primarily caused by direct renal damage (e.g. 
glomurular damage or tubulo-interstitial fibrosis)2, 37 or secondary to the arsenic-induced 
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cardiovascular diseases or other systematic diseases (e.g. cardio-renal syndrome type 5)38, 
39 is still largely speculative.  
 Our study showed that urine arsenic concentration was significantly associated 
with incident CKD and the prospective associations are stronger with increasing outcome 
specificity (e.g., the hazard ratio increased from 1.07 for reduced GFR to 1.49 for renal 
failure). The consistent directionality and sequentially increasing effect size of the point 
estimates strengthened the causal inference between arsenic exposure and kidney disease 
as both information bias and possible reverse causality have been minimized by this 
assessment approach.  Our finding is also consistent with previous studies published in 
Taiwan and Sri Lanka with low-moderate arsenic exposure.40, 41  
Regarding arsenic metabolism, only a relatively small case-control study (125 
cases and 229 controls) from Taipei, Taiwan reported an association between arsenic 
metabolism and chronic kidney disease in the current literature.40 This hospital-based 
case-control study, also conducted in a population characterized by low arsenic exposure 
(arsenic levels in drinking water <10 µg/L), found no association between arsenic 
metabolism, as measured in urine, and CKD defined by eGFR< 60 ml/min/1.73m2 lasting 
for at least 3 months40. However, among study participants with a relative lower plasma 
level of lycopene, they found a higher iAs%, MMA%, or DMA% was associated with 
CKD, although their model did not adjust for total arsenic levels.  The discrepancy in 
findings between our study and the study from Taiwan may be due to the difference in 
study population, study design, sampling methods, and statistical approach. Our study is 
prospective, allowing us to examine the temporal relationship between baseline arsenic 
metabolism and incident CKD. The stability of the Strong Heart Study Cohort and the 
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high retention rate through the 10-year follow up also greatly controlled potential 
selection bias. Finally, our study finding is robust to changing the definition of kidney 
diseases.   
 The role of arsenic metabolism in human is considered to reflect both detoxication 
and  bioactivation.4, 42 The relative potencies of the arsenicals have been proposed as 
follows:  DMA3+ > MMA3+ ≥ As3+ and As5+ > MMA5+ and DMA 5+.43-45 It is therefore 
challenging to predict the arsenic toxicity given the same arsenic exposure as each 
individual may have different capacity to metabolize arsenic. Each arsenic species may 
also have a different affinity for different tissues and different kinetics of deposition and 
redistribution in the body.46 Similar to other methylation processes, the contributions of 
both genetic and environmental factors to the inter-individual variability of arsenic 
metabolism are widely acknowledged.47 The interplay among arsenic metabolism, global 
DNA methylation and one-carbon metabolism may further elaborate the individual 
susceptibility to arsenic-related diseases ranging from cancer, cardiovascular diseases, to 
neurodegenerative disorders.48-50 Our prospective study supported the critical role of 
arsenic metabolism in developing kidney disease, suggesting that the arsenic metabolism 
profile needs to be incorporated into risk assessment of arsenic exposure.   
 Strengths of this study include high-quality data collection and rigorous 
laboratory methods for measuring concentrations of urine arsenic species.19, 30  
Biomarkers of arsenic metabolism are not influenced by the variation in the dilution-
concentration of urine samples.  This study also had some limitations. Both urine arsenic 
concentrations and parameters of arsenic metabolism were measured once at baseline 
visit (1981-1991). However, the temporal stability of arsenic metabolism has been 
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confirmed in repeated samples over a 10-year period.5, 29 The classifications of kidney 
disease are based on single measurement at the follow up visit 2(1993-1995) and visit 
3(1998-1999). However, our findings were robust to different renal outcome definitions 
with high sensitivity and high specificity. Moreover, the associations were stronger for 
outcomes with increasing outcome specificity. Other limitations were potential 
information bias (for instance, the GFR estimation is not based on isotopic 
measurements) and over-adjustment (for example, hypertension, diabetes and fasting 
glucose may be in the causal pathway).  
 
 Conclusions 
 Both urine arsenic concentration and arsenic metabolism are independently and 
prospectively associated with the development of kidney diseases. Eliminating 
environmental arsenic exposure remains essential and further efforts to integrate the 
information regarding arsenic methylation capacity into arsenic risk assessment are 
warranted. Our study is just the very first step in investigating the public health 
implications of arsenic metabolism in kidney diseases.  More research is needed to verify 
our results and further explore the pathogenesis of arsenic-related kidney injury from the 
viewpoints of systemic metabolism, epigenomics, and the interaction with other potential 


































Age, year   54.4 (49‐61.2)  58 (52.4‐64)  56.3 (50.4‐63.1)  55.5 (49.8‐61.8)  53.9 (48.8‐59) 
Male, n(%)  1,349 (42.9)  150 (31.7)  119 (36.1)  80 (38.8)  62 (36.1) 
Location, n(%)           
  Arizona  1,106 (35.2)  192 (40.5)  165 (50.0)  115 (55.8)  111 (64.5) 
  Oklahoma  965 (30.7)  143 (30.2)  79 (23.9)  38 (18.5)  25 (14.5) 
  North and South Dakota  1,072 (34.1)  139 (29.3)  86 (26.1)  53 (25.7)  36 (20.9) 
Education, n(%)           
  No high school  711 (22.6)  123 (26.0)  95 (28.8)  77 (37.4)  52 (30.2) 
  Some high school  749 (23.8)  118 (24.9)  88 (26.7)  50 (24.3)  47 (27.3) 
  High school or more  1,683 (53.6)  233 (49.2)  147 (44.6)  79 (38.4)  73 (42.4) 
Smoking, n(%)           
  Never  997 (31.7)  171 (36.1)  111 (33.6)  70 (34.0)  57 (33.1) 
  Former  1,057 (33.6)  168 (35.4)  122 (37.0)  73 (35.4)  70 (40.7) 
  Current  1,089 (34.7)  135 (28.5)  97 (29.4)  63 (30.6)  45 (26.2) 
Alcohol ,n(%)           
  Never  467 (14.9)  86 (18.1)  53 (16.1)  30 (14.6)  22 (12.8) 
  Former  1,274 (40.5)  215 (45.4)  147 (44.6)  96 (46.6)  81 (47.1) 
  Current  1,402 (44.6)  173 (36.5)  130 (39.4)  80 (38.8)  69 (40.1) 
Body mass index   30.1 (26.6‐34.5)  30.4 (27.0‐34.3)  30.5 (27.4‐34.7)  30.4 (27.3‐34.3)  30.5 (27.4‐34.8) 
Waist‐hip ratio  0.96 (0.91‐0.99)  0.96 (0.93‐1.0)  0.96 (0.93‐1.0)  0.97 (0.94‐1.0)  0.97 (0.93‐1.0) 
Waist circumference (cm)  104 (95‐114)  106 (97‐115)  106 (97‐117)  106 (97‐116)  106 (97‐117) 
Urine creatinine, g/L  1.2 (0.8‐1.7)  1.1 (0.7‐1.5)  1.0 (0.7‐1.5)  0.91 (0.6‐1.3)  0.9 (0.6‐1.3) 




Serum creatinine, mg/dL  0.8 (0.7‐0.9)  0.9 (0.8‐1.0)  0.8 (0.7‐0.9)  0.8 (0.7‐0.9)  0.8 (0.7‐0.9) 
eGFR , ml/min/1.73m2  82.5 (75.7‐94.6)  77.0 (67.8‐90.0)  81.5 (73.9‐93.3)  82.3 (72.9‐94.8)  89.4 (77.5‐107.4) 
Hypertension, n(%)  1,070 (34.0)  217 (45.8)  150 (45.5)  97(52.9)  77(44.8) 
Diabetes mellitus, n(%)  1,503 (47.8)  322 (67.9)  256 (77.6)  187 (90.8)  145 (84.3) 
Fasting glucose, mg/dL∆  115 (100‐178)  159.5 (108‐261)  189 (118‐286)  243.0 (152‐313)  229.5 (132‐310) 
HbA1c, % †  5.6 (5‐8)  7.4 (5.4‐10.5)  8.9 (5.6‐11.0)  10.1 (7.6‐11.3)  9.7 (6.0‐11.3) 
Arsenic exposure            
iAs + methylated arsenic*, 
g/g 
10.3 (6.1‐16.3)  11.8 (6.6‐18.5)  12.9 (7.6‐20.4)  14.6 (8.5‐22.3)  14.6 (10.2‐23.6) 
iAs, g/g  0.8 (0.4‐1.6)  0.8 (0.4‐1.5)  1.0 (0.5‐1.7)  1.1 (0.6‐2.0)  1.2 (0.7‐2.0) 
MMA, g/g  1.4 (0.8‐2.3)  1.5 (0.9‐2.6)  1.7 (1.0‐2.8)  1.9 (1.1‐3.0)  2.0 (1.3‐3.0) 
DMA, g/g  7.7 (4.7‐12.5)  9.2 (5.2‐14.0)  10.0 (5.9‐15.5)  11.1 (6.5‐17.6)  11.2 (7.8‐18.6) 
Arsenic metabolism           
iAs%  8.3 (5.8‐11.2)  7.1 (5.1‐9.9)  7.5 (5.6‐10.0)  7.6 (6.0‐9.9)  7.8 (6.0‐10.0) 
MMA%  13.9 (10.8‐17.4)  13.4 (10.5‐16.3)  13.5 (10.5‐16.4)  13.6 (10.5‐16.4)  13.5 (10.7‐16.3) 


















Model 1  Model 2  Model 3  Model 4  Model 5 
eGFR <60 ml/min/1.73m2           
iAs (0.5‐1.8 μg/L)  0.94 (0.80‐1.11)  0.92 (0.78‐1.09)  0.91 (0.77‐1.07)  0.85 (0.72‐1.01)  0.89 (0.76‐1.04) 
MMA ( 0.8‐2.8 μg/L)  1.13 (0.95‐1.34)  1.13 (0.95‐1.34)  1.15 (0.96‐1.37)  1.10 (0.92‐1.32)  1.04 (0.90‐1.20) 
DMA ( 5.2‐14.7 μg/L)  1.25 (1.06‐1.47)  1.23 (1.04‐1.45)  1.17 (0.99‐1.38)  1.09 (0.92‐1.29)  1.05 (0.92‐1.19) 
iAs + methylated arsenic (6.7‐19.6 μg/L)  1.22 (1.03‐1.45)  1.20 (1.01‐1.43)  1.15 (0.97‐1.38)  1.07 (0.90‐1.29)  1.04 (0.91‐1.19) 
eGFR <60 ml/min/1.73m2 & ≥ 25% drop           
iAs (0.5‐1.8 μg/L)  1.01 (0.83‐1.23)  0.99 (0.81‐1.22)  0.96 (0.78‐1.17)  0.88 (0.72‐1.09)  0.88 (0.73‐1.05) 
MMA ( 0.8‐2.8 μg/L)  1.21 (0.98‐1.48)  1.21 (0.99‐1.50)  1.23 (1.00‐1.52)  1.16 (0.93‐1.44)  1.01 (0.85‐1.20) 
DMA ( 5.2‐14.7 μg/L)  1.38 (1.14‐1.68)  1.35 (1.11‐1.64)  1.26 (1.03‐1.54)  1.15 (0.94‐1.42)  1.01 (0.87‐1.18) 
iAs + methylated arsenic (6.7‐19.6 μg/L)  1.35 (1.10‐1.65)  1.32 (1.08‐1.62)  1.25 (1.01‐1.54)  1.14 (0.92‐1.42)  1.00 (0.85‐1.18) 
eGFR <60 ml/min/1.73m2 & ≥ 25% drop & UACR ≥ 300 mg/g         
iAs (0.5‐1.8 μg/L)  1.09 (0.85‐1.39)  1.06 (0.82‐1.37)  1.00 (0.77‐1.29)  0.87 (0.67‐1.14)  0.86 (0.69‐1.08) 
MMA ( 0.8‐2.8 μg/L)  1.39 (1.08‐1.79)  1.39 (1.07‐1.81)  1.40 (1.07‐1.84)  1.27 (0.96‐1.68)  1.03 (0.83‐1.27) 
DMA ( 5.2‐14.7 μg/L)  1.64 (1.28‐2.09)  1.62 (1.26‐2.07)  1.45 (1.12‐1.87)  1.23 (0.94‐1.61)  1.02 (0.84‐1.24) 
iAs + methylated arsenic (6.7‐19.6 μg/L)  1.58 (1.22‐2.03)  1.56 (1.21‐2.02)  1.41 (1.08‐1.85)  1.20 (0.91‐1.59)  1.00 (0.82‐1.23) 
Renal failure           
iAs (0.5‐1.8 μg/L)  1.21 (0.92‐1.59)  1.20 (0.91‐1.59)  1.15 (0.87‐1.53)  1.02 (0.76‐1.37)  1.00 (0.77‐1.28) 
MMA ( 0.8‐2.8 μg/L)  1.62 (1.23‐2.14)  1.64 (1.24‐2.18)  1.66 (1.24‐2.22)  1.51 (1.12‐2.04)  1.20 (0.94‐1.52) 
DMA ( 5.2‐14.7 μg/L)  1.84 (1.41‐2.40)  1.83 (1.40‐2.40)  1.70 (1.29‐2.26)  1.50 (1.12‐2.01)  1.17 (0.94‐1.46) 



















eGFR <60 ml/min/1.73m2         
  iAs%        (5.8‐11.2)  0.78 (0.68‐0.89)  0.78 (0.68‐0.90)  0.80 (0.70‐0.91)  0.80 (0.70‐0.92)  0.82 (0.72‐0.94) 
  MMA%   (10.8‐17.4)  0.95 (0.83‐1.08)  0.97 (0.84‐1.11)  1.04 (0.91‐1.20)  1.07 (0.93‐1.22)  1.07 (0.93‐1.22) 
  DMA%    (71.7‐82.5)  1.19 (1.04‐1.36)  1.18 (1.02‐1.36)  1.11 (0.97‐1.28)  1.09 (0.95‐1.25)  1.08 (0.94‐1.25) 
eGFR <60 ml/min/1.73m2 & ≥ 25% drop         
  iAs%        (5.8‐11.2)  0.79 (0.67‐0.92)  0.79 (0.67‐0.92)  0.80 (0.69‐0.94)  0.81 (0.69‐0.95)  0.85 (0.73‐0.99) 
  MMA%   (10.8‐17.4)  0.92 (0.79‐1.08)  0.95 (0.81‐1.12)  1.05 (0.89‐1.23)  1.08 (0.92‐1.26)  1.07 (0.91‐1.26) 
  DMA%    (71.7‐82.5)  1.21 (1.03‐1.42)  1.19 (1.00‐1.40)  1.11 (0.94‐1.31)  1.08 (0.92‐1.28)  1.06 (0.90‐1.25) 
eGFR <60 ml/min/1.73m2 & ≥ 25% drop & UACR ≥ 300 mg/g       
  iAs%        (5.8‐11.2)  0.67 (0.55‐0.82)  0.67 (0.55‐0.82)  0.69 (0.57‐0.85)  0.71 (0.58‐0.87)  0.75 (0.61‐0.91) 
  MMA%   (10.8‐17.4)  0.93 (0.76‐1.12)  0.94 (0.77‐1.15)  1.08 (0.89‐1.32)  1.13 (0.93‐1.38)  1.13 (0.93‐1.38) 
  DMA%    (71.7‐82.5)  1.32 (1.07‐1.61)  1.32 (1.07‐1.63)  1.18 (0.96‐1.46)  1.13 (0.92‐1.39)  1.10 (0.90‐1.36) 
Renal failure           
  iAs%        (5.8‐11.2)  0.71 (0.57‐0.89)  0.71 (0.57‐0.89)  0.73 (0.58‐0.91)  0.73 (0.58‐0.92)  0.79 (0.63‐0.98) 
  MMA%   (10.8‐17.4)  0.95 (0.77‐1.19)  0.97 (0.77‐1.21)  1.07 (0.86‐1.34)  1.10 (0.88‐1.37)  1.10 (0.88‐1.38) 



















eGFR <60 ml/min/1.73m2         
iAs% substituted by:           
  MMA%   (10.8‐17.4)  1.54 (1.16‐2.05)  1.58 (1.19‐2.11)  1.77 (1.33‐2.36)  1.81 (1.36‐2.40)  1.69 (1.28‐2.24) 
  DMA%    (71.7‐82.5)  1.77 (1.31‐2.39)  1.78 (1.32‐2.42)  1.86 (1.37‐2.52)  1.86 (1.37‐2.52)  1.73 (1.29‐2.32) 
MMA% substituted by:           
  iAs%        (5.8‐11.2)  0.70 (0.56‐0.89)  0.69 (0.54‐0.87)  0.63 (0.50‐0.79)  0.62 (0.49‐0.78)  0.65 (0.52‐0.82) 
  DMA%    (71.7‐82.5)  0.87 (0.69‐1.11)  0.85 (0.66‐1.08)  0.74 (0.58‐0.94)  0.71 (0.56‐0.90)  0.73 (0.58‐0.93) 
DMA% substituted by:           
  iAs%        (5.8‐11.2)  0.75 (0.65‐0.88)  0.75 (0.64‐0.87)  0.73 (0.63‐0.85)  0.73 (0.63‐0.85)  0.76 (0.66‐0.88) 
  MMA%   (10.8‐17.4)  1.09 (0.94‐1.26)  1.11 (0.95‐1.29)  1.21 (1.04‐1.40)  1.23 (1.06‐1.43)  1.21 (1.04‐1.40) 
eGFR <60 ml/min/1.73m2 & ≥ 25% drop         
iAs% substituted by:           
  MMA%   (10.8‐17.4)  1.44 (1.03‐2.02)  1.52 (1.08‐2.14)  1.76 (1.26‐2.47)  1.82 (1.30‐2.53)  1.64 (1.17‐2.29) 
  DMA%    (71.7‐82.5)  1.69 (1.19‐2.40)  1.73 (1.21‐2.46)  1.83 (1.29‐2.61)  1.84 (1.29‐2.62)  1.64 (1.16‐2.31) 
MMA% substituted by:           
  iAs%        (5.8‐11.2)  0.74 (0.56‐0.97)  0.71 (0.54‐0.94)  0.63 (0.48‐0.83)  0.62 (0.47‐0.81)  0.67 (0.51‐0.88) 
  DMA%    (71.7‐82.5)  0.93 (0.70‐1.23)  0.87 (0.65‐1.17)  0.73 (0.54‐0.97)  0.70 (0.52‐0.93)  0.73 (0.55‐0.98) 
DMA% substituted by:           
  iAs%        (5.8‐11.2)  0.77 (0.65‐0.92)  0.76 (0.64‐0.91)  0.74 (0.62‐0.88)  0.74 (0.62‐0.88)  0.78 (0.66‐0.93) 
  MMA%   (10.8‐17.4)  1.05 (0.88‐1.25)  1.09 (0.91‐1.31)  1.22 (1.02‐1.45)  1.25 (1.05‐1.49)  1.21 (1.01‐1.45) 
eGFR <60 ml/min/1.73m2 & ≥ 25% drop & UACR ≥ 300 mg/g       
iAs% substituted by:           
  MMA%   (10.8‐17.4)  1.98 (1.32‐2.98)  2.06 (1.36‐3.11)  2.34 (1.60‐3.44)  2.40 (1.65‐3.49)  2.23 (1.51‐3.29) 
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  DMA%    (71.7‐82.5)  2.47 (1.58‐3.87)  2.53 (1.62‐3.98)  2.56 (1.66‐3.95)  2.51 (1.64‐3.85)  2.25 (1.47‐3.46) 
MMA% substituted by:           
  iAs%        (5.8‐11.2)  0.57 (0.41‐0.80)  0.56 (0.40‐0.78)  0.50 (0.37‐0.68)  0.49 (0.36‐0.67)  0.52 (0.38‐0.71) 
  DMA%    (71.7‐82.5)  0.81 (0.58‐1.14)  0.78 (0.55‐1.11)  0.64 (0.46‐0.89)  0.61 (0.44‐0.83)  0.61 (0.44‐0.86) 
DMA% substituted by:           
  iAs%        (5.8‐11.2)  0.64 (0.51‐0.80)  0.63 (0.50‐0.79)  0.62 (0.50‐0.78)  0.63 (0.51‐0.78)  0.67 (0.54‐0.82) 
  MMA%   (10.8‐17.4)  1.14 (0.92‐1.40)  1.16 (0.94‐1.44)  1.31 (1.07‐1.61)  1.36 (1.12‐1.66)  1.35 (1.10‐1.67) 
Renal failure           
iAs% substituted by:           
  MMA%   (10.8‐17.4)  1.86 (1.19‐2.91)  1.88 (1.20‐2.95)  2.09 (1.36‐3.20)  2.11 (1.39‐3.21)  1.90 (1.22‐2.96) 
  DMA%    (71.7‐82.5)  2.22 (1.37‐3.59)  2.22 (1.36‐3.60)  2.25 (1.40‐3.63)  2.23 (1.39‐3.59)  1.93 (1.20‐3.11) 
MMA% substituted by:           
  iAs%        (5.8‐11.2)  0.60 (0.42‐0.87)  0.60 (0.41‐0.86)  0.55 (0.39‐0.78)  0.54 (0.39‐0.77)  0.59 (0.41‐0.85) 
  DMA%    (71.7‐82.5)  0.81 (0.55‐1.17)  0.79 (0.54‐1.17)  0.68 (0.47‐0.98)  0.66 (0.46‐0.95)  0.68 (0.46‐1.00) 
DMA% substituted by:           
  iAs%        (5.8‐11.2)  0.67 (0.53‐0.86)  0.67 (0.53‐0.86)  0.67 (0.53‐0.85)  0.70 (0.53‐0.85)  0.72 (0.57‐0.91) 























    MMA%  DMA%  iAs%  DMA%  iAs%  MMA% 
Age (years)               
  < 55  1629  2.42 (1.48‐3.96)  2.32 (1.26‐4.27)  0.49 (0.33‐0.73)  0.55 (0.36‐0.85)  0.66 (0.48‐0.89)  1.44 (1.10‐1.89) 
  ≥ 55   1484  2.30 (1.24‐4.25)  2.55 (1.34‐4.87)  0.51 (0.31‐0.84)  0.66 (0.40‐1.10)  0.63 (0.45‐0.86)  1.29 (0.94‐1.77) 
p‐value for interaction    0.75  0.54  0.75  0.86  0.54  0.86 
Sex               
  Men   1334  2.09 (1.11‐3.93)  2.42 (1.44‐4.08)  0.55 (0.33‐0.92)  0.64 (0.37‐1.12)  0.69 (0.50‐0.94)  1.32 (0.93‐1.86) 
  Women  1779  2.13 (1.13‐4.00)  2.87 (1.52‐5.43)  0.49 (0.32‐0.74)  0.68 (0.45‐1.04)  0.59 (0.43‐0.81)  1.27 (0.97‐1.64) 
p‐value for interaction    0.81  0.81  0.81  0.45  0.81  0.45 
Study site               
  Arizona  1094  3.30 (1.98‐5.49)  4.19 (2.24‐7.84)  0.38 (0.25‐0.57)  0.60 (0.40‐0.91)  0.49 (0.36‐0.67)  1.37 (1.06‐1.76) 
  Oklahoma   960  1.83 (0.61‐5.47)  1.84 (0.57‐5.93)  0.61 (0.25‐1.49)  0.69 (0.29‐1.61)  0.74 (0.41‐1.32)  1.26 (0.75‐2.12) 
  North/South Dekota  1059  1.53 (0.72‐3.25)  1.16 (0.56‐2.41)  0.71 (0.38‐1.31)  0.58 (0.28‐1.20)  0.93 (0.64‐1.34)  1.40 (0.89‐2.18) 
p‐value for interaction    0.38  0.08  0.38  0.99  0.08  0.99 
Smoking               





0.25 (0.13‐0.46)  0.31 (0.17‐0.57)  0.44 (0.29‐0.67)  2.06 (1.41‐3.01) 
  Current  1078  1.98 (0.91‐4.31)  1.83 (0.85‐3.91)  0.57 (0.30‐1.08)  0.60 (0.30‐1.22)  0.74 (0.51‐1.08)  1.37 (0.89‐2.11) 
p‐value for interaction    0.16  0.41  0.16  0.06  0.41  0.06 
Obesity               





0.22 (0.12‐0.39)  0.40 (0.23‐0.70)  0.34 (0.23‐0.51)  1.75 (1.25‐2.45) 
p‐value for interaction    0.03  <0.01  0.03  0.43  <0.01  0.43 
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Waist‐hip ratio               
  Non‐abdominal 
obesity* 
892  2.58 (1.05‐6.36)  2.63 (1.07‐6.42)  0.46 (0.22‐0.96)  0.56 (0.26‐1.23)  0.62 (0.39‐0.97)  1.42 (0.88‐2.31) 
  Abdominal obesity  2221  2.33 (1.50‐3.63)  2.47 (1.47‐4.14)  0.50 (0.35‐0.72)  0.62 (0.43‐0.90)  0.64 (0.49‐0.82)   1.34 (1.06‐
1.69) 
p‐value for interaction    0.61  0.55  0.61  0.82  0.55  0.82 
iAs+MMA+DMA               
 5.5 g/g    782  2.10 (0.49‐8.99)  1.61 (0.37‐7.09)  0.55 (0.17‐1.79)  0.48 (0.16‐1.44)  0.79 (0.38‐1.65)  1.57 (0.80‐3.06) 





0.36 (0.14‐0.92)  0.51 (0.19‐1.36)  0.50 (0.28‐0.88)  1.52 (0.83‐2.79) 
> 13.9 g/g   776  1.85 (1.04‐3.31)  2.20 (1.11‐4.34)  0.61 (0.38‐0.97)  0.81 (0.49‐1.33)  0.67 (0.48‐0.95)  1.14 (0.84‐1.56) 
p‐value for interaction    0.78  0.96  0.78  0.17  0.96  0.17 























 This dissertation describes the role of arsenic metabolism in a broad spectrum of 
health conditions including all-cause mortality, cardiovascular disease mortality, cancer 
mortality, incident diabetes, and kidney diseases based on population-based prospective 
cohort data. Our study is the first to show the dynamic relationship among iAs%, 
MMA%, and DMA%. The data support the hypothesis that certain profiles of arsenic 
metabolism are associated with different chronic diseases. Previous evidence, conducted 
mostly in Taiwan1-3, found that higher MMA% and lower DMA% in urine were related 
to increased risk of developing cancer and cardiovascular diseases while higher DMA% 
and lower MMA% were associated with the risk of obesity and diabetes.4-7 Through 
systematic statistical modeling, we have further advanced the understanding of the 
mutual dynamics among biomarkers of arsenic metabolism and provide important 
information for risk assessment and risk management of arsenic toxicity. This chapter 
summarizes the results of these projects and discusses the implications of the data.  
 
Summary of findings 
 In the first chapter, we conducted a systematic review to identify areas of 
knowledge gap in the risk assessment of arsenic metabolism in different disease 
outcomes including cancer, cardiovascular disease, obesity, and diabetes. For cancer, 
although many studies supported that higher MMA% and lower DMA% were associated 
with the development of cancer especially for urothelial cancer, these studies were 
relatively small and most of them were conducted in Taiwan using hospital-based case-
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control study designs.2 Furthermore, the associations were mostly detected in subgroup 
analyses (interaction analyses) and most prospective studies did not support this 
hypothesis.8-10 The role of arsenic metabolism in cardiovascular diseases remains unclear 
and conflicting. However, two prospective cohort studies from Taiwan and Bangladesh 
showed higher MMA% was associated with carotid atherosclerosis and cardiovascular 
diseases, respectively.11, 12 Few studies examined the association between arsenic 
metabolism and obesity and diabetes.5, 6, 13, 14 Decreasing MMA% was consistently linked 
to the increasing body mass index. However, for diabetes, no specific pattern of arsenic 
methylation capacity was identified in the current literature although very few studies 
have looked at this question and their sample size is relatively small. In addition, the 
statistical modeling of arsenic metabolism was highly heterogeneous across the enrolled 
studies and was not appropriate as all studies ignored the compositional nature of arsenic 
metabolism, which made interpretation and application difficult and prevented 
meaningful statistical inference.  
 In the second chapter, we examined the relationship between arsenic metabolism 
and all-cause mortality, CVD mortality, and cancer mortality in 3,600 adults 45-75 years 
old in American Indian communities from the three centers that participated in the Strong 
Heart Study in the US at the baseline visit in 1989-1991 and had completed information 
on urine concentrations of inorganic arsenic and methylated arsenic species. Vital status 
and cause-of-death codes were determined by annual contact, review of hospitalization 
records and death certificates, and information obtained from National Death Index. 
Through a median follow-up of 17.3 years, 1,559 (43.3%) participants died of any cause, 
484 (13.4 %) died of cardiovascular disease (CVD), and 281 (7.8%) died of cancer.  
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Overall, median concentration of the sum of inorganic and methylated arsenic species in 
the urine was 11.2 μg/L (interquartile range, 6.6 to 19.1μg/L). Urine arsenic 
concentrations were higher in participants from Arizona (median 14.9 μg/L), followed by 
the North and South Dakotas (12.6 μg/L) and Oklahoma (median 7.2 μg/L). The median 
(interquartile range) for inorganic arsenic%, MMA% and DMA% was 8.0 (5.6 to 11.0), 
14.0 (10.8 to 17.6) and 77.7 (71.9 to 82.6), respectively. In multi-adjusted Cox 
proportional hazards model, we found the substitution of iAs% by DMA% was 
prospectively associated with higher all-cause mortality. The substitution of iAs% by 
either MMA% or DMA% was associated with higher cardiovascular disease (CVD) 
mortality. The substitution of DMA% by MMA% was also related to higher CVD 
mortality. For cancer mortality, the substitution of MMA% by either iAs% or DMA% 
was prospectively associated with higher cancer mortality. In addition, we found no 
significant interaction between urine arsenic concentrations and biomarkers of arsenic 
metabolism.   
 In the third chapter, we examined the relationship between arsenic metabolism 
and incident diabetes in 1,694 diabetes-free adults 45-75 years old in American Indian 
communities from the three centers that participated in the Strong Heart Study in the US 
at the baseline visit in 1989-1991 and had completed information on urine concentrations 
of inorganic arsenic and methylated arsenic species. Diabetes was defined as a fasting 
plasma glucose ≥126 mg/dL, venous plasma glucose 2–h after ingestion of 75 g oral 
glucose load ≥200 mg/dL, self-reported diabetes history, and self-reported use of insulin 
or oral hypoglycemic medications. The median urine concentration of the inorganic 
arsenic plus methylated arsenic species was 10.2 μg/L creatinine (interquartile range, 6.1 
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to 17.7 μg/L). Urine arsenic concentrations were higher in participants from Arizona 
(median 14.3 μg/L), followed by the Dakotas (11.9 μg/L) and Oklahoma (median 7.0 
μg/L). The median (interquartile range) for inorganic arsenic%, MMA% and DMA% was 
8.3 (5.7 to 11.3), 15.2 (11.7 to 18.8) and 76.4 (70.3 to 81.4), respectively.  Over 11,263.2 
person-years of follow-up, 396 participants developed diabetes. Diabetes incidence was 
35.2 per 1000 person-years. In multi-adjusted Cox proportional hazards model, we found 
that higher MMA% in urine, either because of lower inorganic arsenic% or lower 
DMA%, was associated with lower incidence of diabetes. We found no significant 
interaction between urine arsenic concentrations and biomarkers of arsenic metabolism.   
 In the fourth chapter, we examined the relationship between arsenic metabolism 
and incident kidney disease in 3,143 adults 45-75 years old with normal renal function in 
American Indian communities from the three centers that participated in the Strong Heart 
Study in the US at the baseline visit in 1989-1991 and had completed information on 
urine concentrations of inorganic arsenic and methylated arsenic species. Incident CKD 
was defined by criteria with increasing specificity to evaluate the sensitivity of the results 
to different outcome definitions.  First, we defined reduced eGFR as an eGFR less than 
60 ml/min/1.73m2. Second, we defined impaired eGFR as an eGFR less than 60 
ml/min/1.73m2 and a drop in eGFR of at least 25%. Third, we defined impaired renal 
function and macroalbuminuria as an eGFR less than 60 ml/min/1.73m2 with a drop in 
eGFR of at least 25% and urine albumin-creatinine ratio ≥ 300 mg/g creatinine. Fourth, 
renal failure was measured by doubling serum creatinine level or progression to end-stage 
renal disease (ESRD). In multi-adjusted Cox proportional hazards model, the hazard ratio 
of incident kidney disease defined by low eGFR (definition 1) for an interquartile range 
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increase in iAs% was 0.62 (95% CI 0.49-0.78) and 0.73 (0.63-0.85) when it substituted 
MMA% and DMA%, respectively. The results were robust to different incident CKD 
definitions. The effects of replacing iAs% by MMA% or DMA% on the risk of 
developing CKD displayed a linear dose-response relationship and were enhanced among 
obese participants defined by body mass index higher than 30 kg/m2. The risk patterns of 
urine arsenic metabolism profiles can be summarized as follows: 1) When the proportions 
of methylated arsenic species increased with a corresponding decrease of the proportion 
of inorganic arsenic, the risk of all-cause and cardiovascular mortality and kidney 
diseases increased. 2) When the proportion of monomethylated arsenic increased with a 
corresponding decrease of the proportion of either inorganic arsenic or dimethylated 
arsenic, the risk of cancer mortality and incident diabetes decreased (Figure 1).  
 
Implications and Future Research 
 Our data support that specific patterns of arsenic metabolism are significantly 
associated with the risk of mortality, diabetes, and kidney disease. Profiles of arsenic 
metabolism reflect inter-individual difference in arsenic methylation capacity and may 
represent the overall effect of host-environmental interaction on arsenic toxicities (figure 
2). Our findings further support the theory that arsenic methylation may be a bio-
activation process rather than just detoxication and also support that different arsenic 
species may have different tissue affinities and pathogenic mechanisms underlying 
different disease phenotypes. Before applying our findings to arsenic risk assessment and 
risk management, Bradford Hill’s causation criteria provides a framework for us to 
identify the gaps and needs to establish causality and inform future research.  
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1. Strength of Association. 
For per interquartile increase in a specific marker of arsenic metabolism that 
replaces two other markers, the hazard ratio for all-cause mortality, cause-specific 
mortality, incident diabetes, and incident kidney disease ranged from 1.04 to 1.83. 
This is consistent with a moderate association.   
2. Temporality and consistency 
The prospective evidence linking arsenic metabolism and mortality, diabetes, and 
kidney disease is scarce. Our findings are not consistent with previous literature 
regarding diabetes and kidney disease.5, 15 However, previous studies were 
relatively small and very few were prospective cohort study designs, making 
evidence interpretation difficult. To establish the consistency of our findings, 
future research is needed to replicate our findings in different populations with a 
larger sample size and consistent statistical modeling to facilitate subsequent 
meta-analysis.  
3. Biological gradient 
In dose-response analysis, we found certain markers of arsenic metabolism are 
linearly associated with the risk of certain endpoints, for instance, with chronic 
kidney disease. However, for all-cause mortality, the relationship was close to a 
threshold dose response.   
4. Specificity 
Our research is not able to support the specificity. However, relevant research 
conducted in Taiwan and Bangladesh may have good opportunities to inform on 
specificity. For instance, Gamble and associate found folate could modify the 
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profile of arsenic metabolism; however, long-term effects of arsenic metabolism 
modification remain unknown.16 In Taiwan, water intervention has been 
implemented for 30 years, a careful follow-up of the change in arsenic 
metabolism and the prevalence/incidence of various diseases can inform the 
specificity of arsenic metabolism.17 Further investigation in this important topic is 
critical to establish a risk management framework of arsenic.  
5. Plausibility, coherence, and experiments 
a. Our findings are coherent with the bioactivation theory of arsenic 
methylation supported by the fact that methylated trivalent arsenicals are 
highly toxic.18-22 MMA(III) is especially of interest to researchers and has 
been considered more potent than arsenite from the perspective of 
cytotoxicity and genotoxicity.23, 24 Recently, DMA(III) was also linked to 
the risk of diabetes in recent cross-sectional studies conducted in Mexico.  
However, systematic evidence evaluating the risk of arsenic species 
remain lacking mainly due to absence of stable measurements of 
MMA(III) and DMA(III) and the lack of standardized methods to adjust 
for differences in urine dilution-concentration especially at low level 
arsenic exposure. In contrast, markers of arsenic metabolism (iAs%, 
MMA%, and DMA%) provide an unique opportunity to model individual 
arsenic methylation capacity and get rid of the issues related to urine 
dilution correction. However, the main challenge of adopting markers of 
arsenic metabolism in risk assessment is the data interpretation, as the 
pathogenesis underlying different patterns of arsenic methylation capacity 
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is unknown. Our research motivates the need to conduct more 
epidemiological and experimental research to study the mechanisms 
underlying the risk patterns of arsenic metabolism. For instance, whether 
the individual methylation capacity of arsenic is linked to the efficiency of 
other methylation reactions remains unknown. Increasing evidence has 
shown a tight interconnection with one-carbon metabolism; however, 
other metabolic pathways may also interplay with arsenic metabolism.25 In 
addition, few evidence studying the genetic and environmental 
determinants of arsenic metabolism in human, more research is urgently 
needed for this fundamental question to assist practical risk management.   
b. On the other hand, as the markers of arsenic methylation capacity may 
represent certain genetic effects on arsenic toxicity, we may use 
metabolism profiles as an instrument variable to control unknown 
confounders and maximize our ability to identify causal effects.   
c. The patterns of arsenic metabolism associated with cardiovascular 
mortality and the risk of developing kidney disease are close to each other, 
supporting the perspective that cardiovascular and kidney diseases may 
share a common metabolic pathogenesis. On the other hand, the similar 
arsenic methylation profiles between cancer mortality and incident 
diabetes could be consistent with a common etiological link. These 
observations are coherent with current perspectives on the etiological 
connections between cardiovascular disease and kidney disease, and 
between diabetes and cancer, respectively.26, 27   
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6. The role of arsenic metabolism in toxicological paradigm 
Previous studies suggested arsenic methylation profiles are potential markers of 
host susceptibility to arsenic exposure based on mostly candidate gene association 
studies and exposure-biomarker interaction analyses. In this dissertation, the role 
of arsenic metabolism in the pathogenesis of mortality, diabetes, and kidney 
disease may be beyond susceptibility as we found no significant statistical 
interaction between arsenic exposure and arsenic metabolism. Moreover, arsenic 
metabolism may be an integrated biomarker of how individuals’ susceptibility and 
vulnerability status respond to arsenic exposure resulting in different tissue 
retention, distribution and excretion and the patterns of this response may 
predispose individuals to various clinical outcomes (Figure 2).   
 
Conclusion 
 Markers of arsenic metabolism are novel risk factors of all-cause mortality, 
cardiovascular mortality, cancer mortality, incident diabetes, and incident kidney 
diseases. Before applying these findings in risk assessment and risk management of 
arsenic toxicity, it would be critical to replicate our results in other populations with 
extensive range of arsenic exposure, with longer follow-up, and with larger sample size.  
At the policy level, in addition to implementing strict control of arsenic exposure, public 
health efforts may focus on risk stratification and patterns of arsenic metabolism may 
guide to conduct risk management and link environmental effects to individual health 
care. At the community and individual levels, we need to build and solidify public 
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awareness of the health risks of arsenic as there may be no safe zone regarding individual 
susceptibility toward arsenic.   
 
Figure 1. Summary of the risk patterns of urine arsenic metabolism profiles with 








Figure 2. The role of arsenic metabolism in the classic toxicological paradigm. SES, 
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